



Department of Medical Biology 
A study of TRIM32 self-ubiquitination 
Waqas Khan 
Master’s thesis in Biomedicine…MBI-3911…May 2020 
 
 
Page 1 of 109 
 





















Page 2 of 109 
 
                            Acknowledgements 
 
 
This research thesis was prepared to fulfill the requirement of Master of Science degree in the 
Department of Medical Biology at the University of Tromsø, Norway and performed at the 
Molecular Cancer Research Group. 
I would like to express my deepest gratitude to my supervisors Eva Sjøttem and Juncal Garcia 
Garcia for good support, encouragement and excellent guidance, which enabled me to 
understand this research work. I am very thankful to my supervisor Eva Sjøttem for her 
guidance in writing and laboratory work. I am also thankful to my co-supervisor Juncal Garcia 
Garcia for her support in better understanding of the different lab techniques. I would also like 
to thank all members of Molecular Cancer Research Group for providing full support during 
my research. 
My sincere thanks to all scientists, phd fellows, Post Docs and technicians especially Gry Evjen, 
Hanne Britt Brenne, Aud, Abudu Yakubu, Anthimi, Katrine Overå, Mireia, Trond, Nikoline 
who worked with me and assisted in the laboratory. I am also thankful to Terje Johansen who 
provide me the opportunity to work in his research group. 



















Page 3 of 109 
 
                                       Abbreviations  
 
 
BafA1: Bafilomycin A1 
BBS11: Bardet-Biedl syndrome 11 
Cas9: CRISPR-associated protein 9 
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats 
CC: coiled-coil domain 
DMEM: Dulbecco's Modified Eagle Medium 
DNA: Deoxyribonucleic acid 
ddNTPs: dideoxynucleotides 
dNTP: deoxynucleotide 
EGFP: Enhanced Green Fluorescent Protein 
gRNA: Guide RNAs  
kDa: kilodalton 
LGMD2H: Limb-girdle muscular dystrophy 2H 
MEM: Minimum Essential Media 
NHL: NCL1, HT2A and LIN41 domain 
PBS: Phosphate Buffered Saline 
PCR: Polymerase chain reaction 
PEST: Proteolytic signal sequences  
p62/SQSTM1: Sequestosome-1 
 
Page 4 of 109 
 
RT: Room temperature 
R-domain: RING finger domain  
TRIM: Tripartite motif (TRIM) proteins 
Ub/Ubi: Ubiquitin 


















Page 5 of 109 
 
                                     Abstract 
 
TRIMs (tripartite motif proteins) constitute a family of ubiquitin E3 ligases that are involved in 
a variety of cellular processes including autophagy and carcinogenesis. TRIM32 contains an 
N-terminal RING finger domain, B-box region, a coiled-coil domain and six NHL repeats in 
the C-terminal region, which are involved in protein dimerization and substrate recognitions. 
Various mutations in the NHL domains are associated with limb-girdle muscular dystrophy 2H 
(LGMD2H). TRIM32 is shown to have the capability to ubiquitinate actin and thus possibly 
participates in myofibrillar protein turnover, especially during the period of muscle 
transformation and adaptation. TRIM32 is activated by self-ubiquitination induced upon 
dimerization. Mass spectrometry analysis of EGFP-TRIM32 expressed in HEK293 FlpIn cells 
suggested three lysine residues, K50, K247 and K401, as putative target sites for the self-
ubiquitination activity. The aim of this work was to investigate the importance of these lysine 
residues for TRIM32 mediated self-ubiquitination. Expression plasmids of EGFP-TRIM32 
single, double and triple mutants were established by site–directed mutagenesis. These mutants 
were transfected into various cell lines and TRIM32 self-ubiquitination analyzed by Western 
blotting. Introduction of single or double K to R mutations did not seem to abolish self-
ubiquitination. However, the double mutant EGFP-TRIM32-K247R/K401R and the triple 
mutant EGFP-TRIM32-K49R/K247R/K401 displayed a faster migration band on the blot, 
suggesting that these proteins were cleaved.  Inhibition of the lysosome or the proteasome did 
not inhibit cleavage of EGFP-TRIM32 K49R/K247R/K401R. Localization studies using 
confocal microscopy showed that both EGFP-TRIM32 WT and the K to R double and triple 
mutants had a tendency to aggregate in cells, clustering with the Golgi protein GM130 and the 
autophagy receptor p62/SQSTM1. Since mutations in TRIM32 leads to muscle dystrophy, the 
second aim of this project was to establish myoblast TRIM32 KO cell lines. These cells would 
represent good model systems for functional analysis of TRIM32 mutations. Guide RNAs 
(gRNA) sequences for mouse and rat TRIM32 were selected by bioinformatics tools and cloned 
into the CRISPR/Cas9 pX458 plasmid. Successfully cloned plasmids were transfected into the 
mouse myoblast cell line C2C12 and the rat myoblast cell line H9c2. Transfected cells were 
selected by cell sorting, and expanded clones analyzed by Western blotting. Two promising 
myoblast C2C12 TRIM32 KO cell lines were successfully established. 
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1. Introduction    
The protein quality control system is essential for cellular health, especially in case of muscles 
and nervous system tissues, which contain long living cells. Dysregulation of protein quality 
control results in protein aggregation and progression of diseases with growing prevalence 
related to age. The two most important biological processes for controlling protein degradation 
are autophagy and the ubiquitin-proteasome system (UPS) (Overa et al., 2019). The mechanism 
of autophagy is considered as a survival pathway, which is utilized by both the normal as well 
as tumor cells to survive during starvation and stress (White and DiPaola, 2009). Human cells 
express more than 10,000 various proteins at any given time. The majority of these proteins 
must fold (and usually gather) to precise, three-dimensional structures to allow a multiple of 
cellular functions. Strongly folded proteins may unfold and perhaps accumulate under various 
stress conditions such as elevated temperatures. When proteins become misfolded as well as 
are no longer functionally needed, they must be degraded to prevent the harmful effects caused 
by their continued existence. This not only requires tough regulation of the initial production 
and folding of a protein, but it also requires conformational maintenance, regulation of 
abundance and subcellular localization and most importantly removal of these proteins by 
degradation (Klaips, Jayaraj, and Hartl, 2018; Balch et al., 2008).  
To maintain protein homeostasis (proteostasis), the cells have developed a broad range of 
molecular chaperones as well as protein quality-control factors, which are functionally 
connected with protein degradation machineries and this system is known as proteostasis 
network. This proteostasis network can be divided into three parts; firstly, protein synthesis, 
secondly folding, trafficking and conformational maintenance, and thirdly protein degradation 
mechanism; the ubiquitin–proteasome system (UPS) and autophagy–lysosome system (Klaips, 
Jayaraj, and Hartl, 2018; Balch et al., 2008).  
 
1.1. Ubiquitin Proteasome system (UPS) 
The process of releasing amino acids from a protein can be differentiated into two parts, which 
are based on the usage of metabolic energy such as ATP followed by ATP-independent events 
(Figure 1). This key model of protein unfolding, which is further followed by degradation is 
conserved and involves various steps. First, in eukaryotes the proteins directed for degradation 
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are generally polyubiquitinated and restrained to regulators for ATP-dependent proteases. 
Second, these proteins are unfolded through regulators by using the way of conformation 
changes directed by ATP hydrolysis. Third, these unfolded proteins are firmly translocated into 
the proteolytic compartments. Finally, polypeptides are degraded by endopeptidases, 
aminopeptidases and carboxypeptidases in an ATP-independent manner (Nandi et al., 2006).  
 
Figure 1: The overall view of the protein degradation pathway in eukaryotes. The whole 
mechanism is followed by the protein degradation, which is leading to free amino acids. The proximal 
steps in this pathway is operated by enzyme of 26S proteasomes, while the latter steps are performed by 
ATP- independent proteases and peptidases (Obtained and modified from Nandi et al., 2006). 
 
Various catabolic conditions have been recognized by activation of a short protein of 76-amino 
acids called ubiquitin (Ub). It is present in all tissues of eukaryotes. The cellular proteins are 
changed and modified by covalent attachment to Ub proteins by a cellular regulatory 
mechanism, which is known as ubiquitination. This ubiquitination mechanism can mark 
proteins for degradation due to the ability of the 26S proteasome complex to identify ubiquitin 
chains, which are connected to proteins. This protein degradation system through the 
proteasome complex is known as ubiquitin-proteasome system (UPS) (Khalil, 2018; Bilodeau, 
Coyne, and Wing, 2016). It plays a significant role in controlling protein turnover and 
coordinating a number of signaling pathways and other central cellular processes (Ito et al., 
2017) such as, cell cycle control, metabolic regulation, apoptosis, development, protein quality 
 
Page 14 of 109 
 
control and antigen presentation. Faults in this system drive to serious diseases such as 
inflammation, cancer and neurodegeneration (Sommer and Wolf, 2014). 
The discovery as well as the identification of both the ubiquitin conjugation pathway and the 
26S proteasome opened a new way into an entirely new world of cellular regulation, which is 
due to their powerful role as the machine degrading polyubiquitinated proteins (Sommer and 
Wolf, 2014). Proteasomes are commonly found in eukaryotes, archaea and some bacteria. The 
26S proteasome found in eukaryotes is a big multi-subunit complex that is used to degrade most 
of the proteins in the cell under normal conditions. This 26S proteasome structure can be further 
divided into two sub-units, the 19S regulatory particle cap and the 20S core particle (Figure 2) 
(Nandi et al., 2006; Budenholzer et al., 2017). 
 
Figure 2: The development of the 26S proteasome by combination of the catalytic 20S proteasome 
with the 19S regulators by using energy in form of ATP (Obtained from Nandi et al., 2006). 
 
1.2. Ubiquitination 
Ubiquitin is a highly conserved protein, which consists of 76-amino acid residues, and is 
normally found in all eukaryotes (Hatakeyama, 2017). Ubiquitination is a post-translational 
modifications process, that results in covalent attachment of the ubiquitin peptide to a target 
protein either in the form of a single unit or chain formats. The ubiquitination regulates various 
intracellular events such as signal transduction, protein stability by protein quality control, 
trafficking and progression of cell cycle, transcription, apoptosis and differentiation (Brigant et 
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al., 2018; Lazzari and Meroni, 2016; Meroni, 2012; Watanabe and Hatakeyama, 2017; van Tol 
et al., 2017; Borlepawar, Frey, and Rangrez, 2019).  The complex process of ubiquitination is 
accomplished by various kind of enzymes, the ubiquitin-activating enzyme (E1), the ubiquitin-
conjugating enzyme (E2) and the ubiquitin ligase (E3). The E3 ubiquitin ligases play main roles 
as receptors for identifying target proteins. The complete pathway of ubiquitination is initiated 
by ubiquitin activation through enzyme E1 that binds to the C-terminal part of a glycine of the 
ubiquitin molecule to its active-site cysteine by using ATP. This creates a high-energy thioester 
bond. The interaction of the E1 enzyme with ubiquitin clear a site to admit the entry of the next 
enzyme. By using a trans-thiolation reaction, the ubiquitin is transported from the E1 to the E2 
conjugating enzyme active-site cysteine, which is known as ubiquitin conjugation by E2 
enzyme. Once the ubiquitin is bound, ubiquitin ligation by an E3 ligase is initiated. The E3 
ubiquitin ligase merges with an E2-ubiquitin conjugate and supports in the transport of the 
ubiquitin from the E2 onto a target protein (Figure 3) (Brigant et al., 2018; Watanabe and 
Hatakeyama, 2017; van Tol et al., 2017; Borlepawar, Frey, and Rangrez, 2019; Meroni, 2012). 
Beside the role of ubiquitination in the protein degradation pathways it is involved in various 
basic cellular approaches, which includes the cell cycle progression, DNA repair, gene 
transcription, virus budding, receptor endocytosis and apoptosis (Khalil, 2018). 
Figure 3: The complete mechanism of ubiquitination is relied upon three enzymatic steps. 
Firstly, it initiates when an E1 ubiquitin-activating enzyme binds to and activates ubiquitin. This 
activated ubiquitin is further used to trans-thiolated purposes from E1 to an E2 ubiquitin-conjugating 
enzyme. Finally, E3 ubiquitin ligases mediate ubiquitin transportation onto the substrates either in the 
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form of directly from E2 to the substrate (RING-type E3s) or by the formation of an E3-ubiquitin 
intermediate (HECT-type E3s) (Obtained from Zou, Levy-Cohen, and Blank, 2015).    
 
1.3. Ubiquitin signaling 
The intracellular signaling by using the covalent attachment of various ubiquitin linkages to 
protein substrates is important for many cellular pathways (Zhang, Smits, et al., 2017). Protein 
ubiquitination is induced and performed by a wide range of stimuli and important signaling 
actions that are performed in cells. These includes a variety of cell surface receptors, which 
become ubiquitinated at the stage of stimulation by extracellular ligands. Additionally, the 
functions of ubiquitin ligases are tightly regulated by signal-induced mechanisms (Haglund and 
Dikic, 2005). The mechanism of mono-ubiquitination is involved in the endocytosis of plasma 
membrane proteins, the sorting of proteins to the MVB (multivesicular body). Moreover, it is 
involved in DNA repair, budding of retroviruses, histone activity as well as transcriptional 
regulation (Haglund, Di Fiore, and Dikic, 2003). Ubiquitination is capable to regulate signaling 
non-proteolytically as it can be used to recruit proteins, which perform specific signaling 
pathways by attracting trafficking factors. These factors are used to alter substrate’s localization 
and to control a substrate’s activity (Komander and Rape, 2012). Ubiquitination may also 
change the function of various proteins. For example, mono-ubiquitination can change protein 
activity and subcellular localization, while K48 poly-ubiquitination targets substrates for 
proteasomal degradation and K63 or linear polyubiquitin chains provide as protein-protein 
interaction platforms, which are further used to mediate signal transduction (Zhang, Smits, et 
al., 2017; Ronai 2016).   
There are different types of ubiquitin linkage chains (Figure 4). A chain of polyubiquitin is 
made of ubiquitin, which contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48, and Lys63) that can be linked by another ubiquitin molecule. The polyubiquitin chains 
are forked chains of ubiquitin, which are linked either via equal or different lysine residues. 
Furthermore, many studies show that besides an internal Lys, the ubiquitin can also be attached 
to other residues, which are found on the substrate; the N-terminal residue, an internal Thr or 
Ser (to produce an ester bond), or Cys (to produce a thiol ester bond) (Figure 5). The cellular 
fate of an ubiquitinated protein is normally depending on the form or which type of ubiquitin 
linkage is found. For example, determination of protein subcellular localization, regulation of 
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different signaling pathways, transcription factors, protein kinases and controlling the duration 
as well as magnitude of a protein’s activity (Zhang, Smits, et al., 2017; Ronai, 2016; van der 
Aa et al., 2012; Livneh et al., 2017). 
 
 
Figure 4: Various kinds of protein 
ubiquitination. (A) Monoubiquitination, (B) 
Multimonoubiquitination, (C) Homogenous 
polyubiquitin chain, (D) Mixed polyubiquitin 
chain, (E) Branched polyubiquitin chain, and 
(F) Unanchored. (Obtained from Bielskienė et 
al., 2015). (G) The two adverse looks of 
ubiquitin shown. Ubiquitin has seven Lysine 
residues and all of them can be used for chain 
formations. The Lys48- and Lys63- connected 
chains are the best described and are probably 
the most common. Due to the possible options 
in the spot and type of ubiquitination, the 
potential configurations are broad for ubiquitin 
modifications. All Lysine are shown by white 
color with the ɛ-amino-group nitrogen atoms 
(blue color). All the ubiquitin-binding domains 
that have been described so far touch an 
overlapping face ubiquitin that combines Ile44 
(red color) (Obtained from Hicke, Schubert, and 
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Figure 5: Different sites of ubiquitination. (A) Ubiquitination found on internal Lys residues (B) 
Ubiquitination found on residues other than Lys such as Ser, Thr, Cys (C) Ubiquitination found on the 
N‐terminal residue (Obtained from Livneh et al., 2017). 
 
1.4. Autophagy 
Autophagy is a Greek word in which “auto,” meaning oneself and “phagy” meaning to eat 
(“self-eating”). This word defines an intracellular process in which cytoplasmic components 
are transported to the lysosome for degradation. The basic term of autophagy was first 
introduced by the Nobel laureate Christian de Duve on 1963 in London (Bhutia et al., 2013; 
Barbosa, Grosso, and Fader, 2019). Autophagy is a degradation pathway in which both cellular 
components and proteins are absorbed by autophagosomes and further digested in the 
lysosomes. This pathway is important for cellular homeostasis and cellular metabolism (Duffy 
et al., 2015). There are three main types of autophagy, macroautophagy, microautophagy and 
chaperone-mediated autophagy. All are used to recognize and degrade various internal cellular 
constituents (Bhutia et al., 2013; Kimura, Mandell, and Deretic, 2016). Macroautophagy 
includes the packaging of cytosolic components into a double layered vesicle called 
autophagosome. The autophagosome fuse with the lysosomes, where the autophagosomal 
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content is degraded by the lysosomal proteases. The building blocks of the degraded 
macromolecules are recycled back to the cytosol for reuse. Microautophagy involves the direct 
absorption of the cytosolic components into the lysosome via invagination of the lysosomal 
wall. Finally, the Chaperone-mediated autophagy uses chaperone proteins for the direct transfer 
of cytosolic components across the lysosomal wall (Figure 6) (Wilde et al., 2018). 
 
Figure 6: Three different types of autophagy. The transfer of cytosolic protein aggregates, 
organelles and intracellular pathogens into the lysosome bodies for degradation (Obtained from 
Barbosa, Grosso, and Fader, 2019). 
 
The main role of autophagy is to provide nutrients, which are important for performing cellular 
activities especially during the condition of fasting and other forms of stress faced by the cell. 
Autophagy was long considered as a nonselective process. Later autophagy was shown to 
mediate selective removal of unwanted as well as toxic cytosolic material, such as damaged 
mitochondria and protein aggregates (Dikic and Elazar, 2018). Several types of pathological 
conditions such as neurodegeneration, aging, liver failure, inflammatory bowel disease, 
infection and metabolic disorders, other chronic diseases and especially cancer have been 
related to dysfunction or defects in autophagy (Barbosa, Grosso, and Fader, 2019; Lozy and 
Karantza 2012; Choi, 2012). Similarly, deficiency in the autophagy mechanism promotes 
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genomic instability and the DNA damage response (White, 2016). Dysregulation of autophagy 
is ultimately connected with the accumulation of oncogenic mutations and also raises chances 
for susceptibility of tumor growth (Choi, 2012). Autophagy provides a protective and defensive 
role for the host in the case of immunity, inflammation and the resistance during microbial 
infections (Dong et al., 2020).    
p62 is a ubiquitin-binding protein that is encoded by the SQSTM1 or polyubiquitin-binding 
protein sequestosome 1 gene (Dong et al., 2020).  p62/SQSTM1 is expressed in most cells and 
tissues and is distributed both in the cytoplasm and in the nucleus. p62/SQSTM act as an 
autophagy receptor that recognizes and shuttles ubiquitinated proteins to the autophagosome 
for degradation. This ability of p62/SQSTM1 to act as an autophagy receptor depends on three 
important interactions. Firstly, p62 directly interacts with selected cargoes and uses its C-
terminal ubiquitin associated (UBA) domain to combine with ubiquitinated cargoes. Secondly, 
p62 interacts with ATG8s (autophagy-related 8 proteins) attached via their lipid tail to the inner 
membrane of the phagophore. This interaction of autophagy receptors with ATG8s is important 
for selective autophagy. It is mediated by a motif called LC3-interacting region (LIR). Thirdly, 
homo polymerization of p62 mediated by its PB1 domain promotes its co-aggregation with the 
cargo. The polymerization also allows a tight communication of the p62-coated cargo with 
lipidated ATG8s at the phagophore (Darvekar et al., 2014; Lamark, Svenning, and Johansen, 
2017; Ciuffa et al., 2015). p62/SQSTM1 has appeared as a polymeric, modular protein with 
demanding roles in autophagy, protein aggregation and cell signaling. Similarly, dysregulation 
of p62 has been involved in various diseases such as cancer and inflammation 
neurodegenerative disorders (Ciuffa et al., 2015). 
 
1.5. TRIM Proteins 
TRIMs (tripartite motif proteins) constitute a family of E3 ligases that are generally dispersed 
in insects, teleost’s and higher level of vertebrates (Luo et al., 2017). The TRIM proteins are 
also known as RBBC (RING domain, B boxes of the B1 and B2, and a coiled-coil domain) 
proteins. These proteins are characterized by their common tri-partite domain organization, the 
highly conserved order of domains in the N-terminal region. The tripartite motif consists of a 
Really Interesting New Gene (RING) domain, one or two zinc-finger domains that is known as 
B-boxes (B1 and B2) and a coiled-coil (CC) domain (Figure 7A). Both the RING as well as B-
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box domains consist of a zinc-binding motif (Kimura, Mandell, and Deretic, 2016; Lee 2018; 
Crawford, Johnston, and Irvine, 2018; Zhang et al., 2015). The RING domain is found in 
hundreds of other proteins whereas the B-box domain is a critical determinant of the tripartite 
motif (Meroni and Diez-Roux, 2005). Most of the TRIM family proteins have E3 ubiquitin 
ligase activity due to the N-terminal RING-finger domain. Both the B-Box and CC domains 
are shown to mediate self-association activity. The CC domain region is approximately 100 
residues long and is primarily involved in homo-interactions and establishment of higher level 
of molecular-mass complexes (Zhang et al., 2015; Lukic and Campbell, 2012). TRIMs gain 
additional characteristics in the variety of their C-terminal domains. The C-terminal regions, 
which are found on TRIM proteins are divergent and can constitute of various protein-protein 
association domains (Gushchina et al., 2018). This C-terminal region includes a specific 
domain such as the frequently found B30.2 domain, which is also called RFP-like domain. This 
domain with 170-residues also consists of two types of sub-domains such as PRY and SPRY 
domains, which mediates protein–protein interactions (Zhang et al., 2015). The TRIM proteins 
are involved in a huge array of intracellular functions but generally, they function as a part of 
larger protein complexes and also maintain ubiquitin-protein isopeptide ligase activity (Short 
and Cox, 2006). Basically, E3 ubiquitin ligases are the form of proteins that perform post-
translational modification of targets by ubiquitin-modifying reactions, which result in the 
combination of a wide range of ubiquitin modifications on a target substrate (Kudryashova et 
al., 2009).   
The human TRIM family of proteins can be categorized into 12 sub-classes based on the 
domains, which are found in the C-terminal region (Figure 8). The TRIM family in humans has 
approximately 80 known members (Zhang, Wu, et al., 2017; Boyer et al. 2018; Tomar and 
Singh 2015; Wang et al. 2011). All the subfamilies of TRIMs comprised of C-I to C-XI groups 
in which the largest number of TRIMs family members are found in the C-IV group. These 
TRIMs include the SPRY/B30.2-like domain, a conserved region whose function is considered 
to be involved in protein-protein interactions or responsible for binding of RNA. The C-XII 
TRIM proteins lack the RING domain (Tomar and Singh, 2015; Wang et al., 2011). TRIMs 
have received an increasing research interest due to their important roles in a variety of cellular 
processes such as intracellular signaling, DNA repair, cell growth, differentiation, 
development, apoptosis, inherited immunity, protein quality control, autophagy and 
carcinogenesis (Figure 7B) (Overa et al., 2019; Hatakeyama, 2017; Brigant et al., 2018; 
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Kimura, Mandell, and Deretic, 2016; Luo et al., 2017). TRIMs also show involvement in 
defense against viral pathogens or cell-autonomous antiviral defense (Kimura, Mandell, and 
Deretic, 2016).  
 
 
Figure 7: The general overview of TRIM protein domain structure, diverse functions as 
well as associated diseases. (A) A diagrammatic of the structure of TRIM proteins. TRIMs consist 
of the RBCC motif (RING domain, B boxes, which contains both the B1 and B2, and a coiled‐coil 
domain) along with the C‐terminal domain, which also serves as protein binding domain. The RING 
domain part of TRIMs have been deliberate E3 ligase activity, while the changeable part of the carboxy-
terminal region determinates substrate specificity. (B) The biological roles of TRIM proteins are diverse 
in many respects and includes a direct viral restraint by targeting retroviral capsids for degradation, 
immune signaling through the processs of polyubiquitination, direct proteins to autophagy, cellular 
proliferation, differentiation and apoptosis; TF: transcription factor (Obtained from Vunjak and 
Versteeg, 2019; Khan et al., 2019).  
 
Most of the TRIM proteins display E3 ubiquitin ligase activity (Watanabe and Hatakeyama, 
2017) due to the possession of a RING-finger domain (Hatakeyama, 2017). Similarly, the 
ubiquitination of particular substrates is one of the major mechanisms by which TRIM proteins 
utilize their biological functions (Lazzari and Meroni, 2016). Mutations in many human TRIM 
genes result in various kinds of genetic diseases. These genetic diseases include mulibrey 
(muscle-liver-brain-eye) nanism  due to mutations in TRIM37, Opitz syndrome due to the 
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mutations in TRIM18/MID1, muscular dystrophy limb-girdle Type 2H and Bardet-Biedl 
syndrome 11 due to various mutations in TRIM32 and familial Mediterranean fever associated 
with mutations in TRIM20/MEFV (Marin, 2012). Nowadays, both the researchers and 
clinicians are increasingly concerning TRIMs due to their roles found in cancer development 
and progression (Chen et al., 2019).  
 
 
Figure 8: Based on the C-terminal region the structural classification of the TRIM family 
of proteins are shown. Most of the TRIM family proteins consists of a N-terminal RING domain, 
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one or two B-box domains (B1 and B2) and a coiled-coil domain (CC). TRIM proteins are classified 
into 11 subfamilies, which are based on a variable C-terminal domain such as C-I to C-XI. There is also 
one additional unclassified group, which is lacking a RING finger domain. Those TRIM family 
members, which are insufficient of one or more domain as shown in dark brackets and illustrated by a 
dashed outline. The complete list of TRIM proteins, which are found in each class is on the right side. 
Pyrin, Pyrin domain; FN3, fibronectin type 3 repeat; COS, C-terminal subgroup one signature;  PRY, 
PRY domain; SPRY, SPRY domain; PHD, plant homeodomain;  ACID, acid-rich region; FIL, filamin-
type immunoglobulin domain; NHL, NCL1, HT2A and LIN41 domain; BROMO, bromodomain; 
ARF, ADP-ribosylation factor family domain; MATH, meprin and tumor-necrosis factor receptor-
associated factor homology; TM, transmembrane region (Obtained from Crawford, Johnston, and 
Irvine, 2018).   
 
1.6. TRIM32   
TRIM32 is a member of the TRIM family proteins consisting of 653 amino acids and a 
molecular weight of approximately 72 kDa. It includes a RING finger domain, a B-box region, 
a coiled-coil domain and six NHL repeats in the C-terminal region, which are involved in 
protein dimerization and substrate recognitions (Figure 9) (Ito et al., 2017; Shieh, Kudryashova, 
and Spencer, 2011; Di Rienzo et al., 2019). TRIM32 is a human protein, which was originally 
named HT2A. This protein was first recognized as a mediator of the biological activity of the 
lentiviral TAT protein (Tocchini and Ciosk, 2015). The gene of TRIM32 consists of two exons 
with the full open reading frame included in the second exon (Shieh, Kudryashova, and 
Spencer, 2011). TRIM32 mutations in the NHL domains are associated with limb-girdle 
muscular dystrophy 2H (LGMD2H) and sarcotubular myopathy (STM) (Servián-Morilla et al., 
2019). TRIM32 plays an important role in skeletal muscle cells and its expression is generally 
elevated in muscles that are experiencing remodeling and during myogenic differentiation 
(Meroni, 2012). TRIM32 is shown to have the capability to ubiquitinate actin and thus possibly 
participates in myofibrillar protein turnover, especially during the period of muscle 
transformation and  adaptation (Meroni, 2012). The Limb-girdle muscular dystrophies 
(LGMDs) are a heterogeneous group of initial myopathies with both the autosomal dominant 
and autosomal recessive manner of inheritance (Frosk et al., 2002). LGMD2H affects the 
muscles especially in the regions of the thighs, shoulders, pelvic area and upper arms area. It is 
inherited as an autosomal recessive trait (Watanabe and Hatakeyama, 2017). A TRIM32 
mutation in the B-Box is associated with Bardet-Biedl syndrome 11 (BBS11) and it is an 
extremely heterogeneous human obesity syndrome. This syndrome is also distinguished by 
retinal deterioration, cognitive impairment, renal and cardiovascular abnormalities (Cohen et 
al., 2012; Chiang et al., 2006; Saccone et al., 2008).  
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Figure 9: TRIM32 domain structure. The domain structure of TRIM32 along with localization of 
the human pathogenic mutations, limb-girdle muscular dystrophy 2H at the NHL domain and BBS11 
(Bardet–Biedl syndrome 11) at B-box region (Obtained from Shieh, Kudryashova, and Spencer, 2011). 
 
The extended RING domain of TRIM32 is crystallized as a dimer unit. This whole structure 
forms a four‐helix bundle (Figure 10) (Koliopoulos et al., 2016). 
                                
Figure 10: Ring domain structure of TRIM32. TRIM32 RING dimer structure in ribbon 
illustrates with each RING monomer and colored in cyan and blue and the Zn2+ ions as shown in grey 
spheres (Obtained from Koliopoulos et al., 2016). 
 
TRIM32 is found to be upregulated in various kinds of cancers and its overexpression is shown 
to promote cell oncogenic transformation as well as tumorigenesis in a largely p53-dependent 
way. It is found to facilitate degradation of the tumor suppressors Abi2 and thereby act as a 
proliferative agent (Lazzari and Meroni, 2016; Tocchini and Ciosk, 2015; Liu et al., 
2014). TRIM32 overexpression is directly associated with poor prognosis of hepatocellular 
carcinoma, gastric cancer, and breast cancer (Ito et al., 2017; Du et al., 2018; Cui et al., 2016; 
Zhao et al., 2018). These findings support that TRIM32 acts as an oncoprotein and a predictor 
of malignant cancer (Ito et al., 2017). Patients with Alzheimer’s disease are shown to display 
up-regulation of TRIM32 in the occipital lobe and in psoriasis lesions. TRIM32 is shown to 
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have an influential role in cell polarity, cell division, mobility, neuronal function and metastasis, 
all of which are dependent upon alterations in the cytoskeleton and actin filament building 
(Cohen et al., 2012). Identified TRIM32 substrates are muscular proteins as well as proteins, 
which are involved in cell cycle regulation and cell motility (Lazzari and Meroni, 2016). 
Recently, various members of the TRIM family proteins were shown to promote autophagy 
induction via the crucial autophagy initiator proteins ULK1 (Unc-51 like autophagy activating 
kinase 1) and BECLIN 1. Moreover, some TRIM proteins also serve as cargo receptors for 
selective autophagy (Di Rienzo et al. 2019). In addition, some of the TRIM family proteins 
such as TRIM30 and TRIM50 are degraded by autophagy themselves (Overa et al., 2019). 
Similarly, TRIM32 promotes TAX1BP1-mediated selective autophagic degradation of TLR3/4 
adaptor protein TRIF (Yang et al., 2017). Recent research shows that TRIM32 is degraded by 
autophagy and that it affects the autophagic activity of p62/SQSTM1. Lysosomal degradation 
of TRIM32 was dependent on the autophagic gene autophagy-related 7 (ATG7) and blocked 
by knockout of the five autophagy receptors p62, NBR1, NDP52, TAX1BP1 and OPTN, 
indicating towards degradation by selective autophagy. The p62/SQSTM1 directed TRIM32 
for lysosomal degradation, whereas TRIM32 mono-ubiquitylated p62 on lysine residues 
involved in the regulation of p62/SQSTM1 activity (Overa et al., 2019). 
 
1.7. Generation of knock out cells by CRISPR /Cas9 
The CRISPR (Clustered regularly interspaced short palindromic repeats) and Cas proteins form 
the adaptive CRISPR–Cas immune system in bacteria and archaea. This DNA-encoded as well 
as RNA-mediated defense system supports the sequence-specific identification, targeting and 
degradation of external nucleic acids (Barrangou, 2015). The microbial CRISPR-Cas system 
containing the Cas9 nuclease is conducting specific genomic loci by using a 20-nucleotide 
guide sequence (gRNA) (Ran, Hsu, Lin, et al., 2013). The Cas9 nuclease is guided by this 
gRNA molecule to the target DNA molecule by Watson-Crick base pairing. The guide 
sequences are found inside the CRISPR RNAs usually correlates to phage sequences, which 
are used for establishing the natural mechanism for CRISPR antiviral defense system. The 
gRNA sequence can easily be edited to a sequence of interest to target the Cas9 to a specific 
genomic loci (Hsu, Lander, and Zhang, 2014). The effectiveness and ease of Cas9 endonuclease 
have led to the production of genomic wide CRISPR-knockout (KO) libraries used for both 
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mouse and human cells. These libraries are now widely available in public plasmid archives 
and are typically optimized to gain equal description and performance across all expressed 
gRNAs and contain an antibiotic or fluorescent selection marker that can be further used to 
retrieve transduced cells (Yu and Yusa, 2019). 
The CRISPR/Cas9 system has been used by thousands of laboratories for targeted genome 
editing applications in a various range of experimental model systems. The wild-type Cas9 
nuclease has facilitated both the effective and targeted genome modification in various species 
that have been impossible using traditional ways of genetic manipulation techniques. For 
example, various proteins or RNAs can be restrained to Cas9 to change transcription states of 
precise genomic loci, control of the chromatin states, or even rearranging the three-dimensional 
arrangement of the genome. The ease of Cas9 targeting is obtained due to its high efficiency as 
a site-specific nuclease. Similarly, the possibility for multiplexed modifications have opened a 
wide range of biological applications for Cas9 in the field of biotechnology and medicine (Hsu, 
Lander, and Zhang, 2014).  For example, some studies show that CRISPR/ Cas9–mediated 
genome editing technology is possible in adult animals and also provide a promising 
opportunity for correction and alteration of human genetic diseases (Yin et al., 2014).  
 
2. Aim of the study 
The main aims of this study were to:  
(a) Identify self-ubiquitination sites in TRIM32. 






Page 28 of 109 
 
3. Materials and Methods  
3.1. Materials  
 
Table 1: Growth medium used for bacterial cell cultures and mammalian cell 
lines 
Types Media Contents 
Growth media used for 
bacterial cultures 
LB (Luria-Bertani) medium 10g of Bacto Tryton 
5g of Bacto yeast extract 
10g NaCl  
dH2O up to 1 liter 
NaOH (pH adjusted to 7.5) 
 
Antibiotic used: 
 Ampicillin (100 μg/ml) 
      or 
 Kanamycin (50 μg/ml) 
 
LB agar Plate 10g of Bacto Trypton 
5g of Bacto yeast extract 
10g NaCl  
15g agar 
1 liter of dH2O 
NaOH (pH adjusted to 7.5) 
 
Antibiotic used: 
 Ampicillin (100 μg/ml) 
      or 
 Kanamycin (50 μg/ml) 
 
SOC media (Super optimal 
broth with catabolic 
repression) 
20g of Bacto Trypton 
5g of Bacto yeast extract 
0.5g NaCl 
10ml 250mM KCl 
5g MgCl2 
20mM glucose 
1 liter of dH2O 
NaOH (pH adjusted to 7.5) 
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Growth media used for 
Mammalian cell lines 
 
 
Growth media for mammalian 
cell culture (HeLa cell, MCF-
7 breast cancer cell line, 
HEK293 FlpIn TRIM32 KO 
cell line, 
C2C12 mouse myoblast cell 
line and the H9c2 rat myoblast 
cell lines) 
 
Eagles minimum essential 
medium or MEM (Sigma, 
M4655) 
Supplemented with 10% Fetal 
Bovine Serum (biowest, 
S181B), 1% penicillin (100 
U/ml) and streptomycin (100 
g/ml) (Sigma, P4333) 
Dulbecco's Modified Eagle 
Medium or DMEM (Sigma, 
D6046) 
Supplemented with 10% Fetal 
Bovine Serum (biowest, 
S181B), 1% penicillin (100 
U/ml) and streptomycin (100 
g/ml) (Sigma, P4333) 
 
Growth media for mammalian 
cell culture (MDA-MB-231 
breast cancer cell line) 
 
Roswell Park Memorial 
Institute or RPMI (Sigma, 
R8758) Supplemented with 
10% Fetal Bovine Serum 
solution (biowest, S181B), 
1% penicillin 
(100 U/ml) and streptomycin 
(100 g/ml) (Sigma, P4333) 
 
Trypsin Solution (Sigma, 
T3924) 
 
0.25% of Trypsin 
0.05% of EDTA 
in 1x PBS 
pH adjusted to 7.5 
 




 1% Bovine serum albumin 1g bovine serum albumin 
(Sigma) was mixed with 20 
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Table 2: General buffers 








TE buffer 10mM Tris-HCL with pH 8 
1mM EDTA 
 
6xT gel loading buffer 
 
 
0.25% Bromophenol blue  
60mM EDTA with pH 8.0 
0.6% SDS 
40% (W7v) sucrose  
Sterile filtered  
20x Minigel buffer 193.75 g Tris-Cl 
27.22 NaOAc 
14.9 g EDTA 
dH2O upto the 21 
 
1x Phosphate buffer saline 
(PBS) 
0.1mM Na-phosphate buffer 
solution with pH 7.2 
0.7% NaCl 
1-kb ladder 1 μl 1-kb ladder stock (1.03 μg/μl) 
24 μl TE buffer with pH 8.0 
5 μl of 6xT gel loading buffer 
 
SDS- PAGE  4 x Separating gel buffer 181.65g Trizma-base 
4g SDS  
dH2O up to 11  
pH adjusted to 8.8 with HCl 
 
4 x Concentrating gel buffer 60.55g Trizma-base 
4g SDS  
dH2O up to 11  
pH adjusted to 6.8 with HCl 
 
8 % Separating gel 5.4 ml of H2O  
Separating buffer is 2.5 ml 
40% acrylamide is 2 ml 
10% APS is 100 μl 
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10 % Separating gel 4.9 ml of H2O  
Separating buffer is 2.5 ml 
40% acrylamide is 2.5 ml 
100 μl 10% APS  
10 μl TEMED  
(Tetramethylethylenediamine) 
4 % Concentrating gel H2O = 6.4 ml 
Concentarting buffer is 2.5 ml 
40% acrylamide 1 ml 
10% APS 100 μl 
TEMED 10 μl 
(Tetramethylethylenediamine) 
5x loading buffer 312.5mM Tris/HCl 
20% Sucrose 
10% SDS 
0.1% Bromophenol blue 
2 x loading buffer  5x loading buffer (4 ml) 






1x Transfer buffer 300mM (36.3g) Tris-base 
300mM (22.5g) Glycine 
200 ml methanol 
2.5 ml of 20% SDS 
800 ml dH2O 
5% dried milk solution 2.5 g dried milk 
50 ml 1x TBS-T 
5% Ponceau staining 
Solution 
1g Ponceau S staining 
Acetic Acid 50ml 
1000 ml dH2O 
 
PBS-T buffer 1000 ml 10x PBS (pH 7.4) 
10 ml Tween 
8990 ml dH2O 
 
1xTBS-T buffer 75ml of 2M NaCl 
10ml of 1M Tris-HCl, pH 8.0 
1 ml Tween20 (Sigma, P9416) 
914 ml dH2O 
 
 







10x NEBuffer 2.1 50mM HCl 
10mM Tris-HCl 
10 mM MgCl2 
BSA 100 μg/ml 
(pH 7.9 at 25 oC) 
CutSmart Buffer 50mM Potassium Acetate 
20mM Tris-Acetate 
10 mM Magnesium Acetate  
BSA 100 μg/ml 
(pH 7.9 at 25 oC) 
 
Table 3: Primers used for site-directed mutagenesis and establishment of 
CRISPR/Cas9 gRNA plasmids 
Name Primer sequence Source 
 
TRIM32-K49R 5’-TGCCGCCAGTGCCTGGAGCGCCTATTGGCCAGTAGCATC- 3’ 
5’-GATGCTACTGGCCAATAGGCGCTCCAGGCACTGGCGGCA- 3’ 
This study 
TRIM32-K247R 5’-TACTTCCTGGCCAAGATCCGCCAGGCAGATGTAGCACTA- 3’ 
5’-TAGTGCTACATCTGCCTGGCGGATCTTGGCCAGGAAGTA- 3’ 
This study 
TRIM32-K401R 5’-ATACAAGTCTTTACCCGCCGCGGCTTTTTGAAGGAAATC- 3’ 
5’-GATTTCCTTCAAAAAGCCGCGGCGGGTAAAGACTTGTAT- 3’ 
This study 
CRISPR Mouse T1 5’-CCAGCAGTGTCTGTTTCTCAAG- 3’ 
5’-CTATCAGTGACACCAATCAGCC- 3’ 
This study 
CRISPR Mouse T2 5’-GAAGGCACAGTCTACTTCACCC- 3’ 
5’-AGGTAAGGCCCTCTCGAATAAG- 3’ 
This study 
CRISPR Rat T1      5’-TGATGCTGAAGGCACAGTCTAT- 3’ 
5’-AGGTAAGGCCCTCTCGAATAAG- 3’ 
This study 
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Table 4: Primary and Secondary Antibodies 







Ab290 1:5000 Abcam 
TRIM32 antibody 
(Rabbit) 
10326-1-AP 1:2000 Proteintech 
p62 antibody (Mouse) 610833 1:2000 BD Biosciences 
LC3B antibody L7543 1:1000 Sigma 
PCNA Antibody 
(Mouse) 
M0879 1:2000  DAKO  
Actin Antibody 
(Rabbit) 
A2066 1:1000  Sigma  
GM130 antibody 
(Rabbit) 










554021 1:2000 BD Biosciences 
HRP-conjugated anti-
biotin antibody 
#7075 1:2000 Cell signaling 
Alexa Fluor® Rabbit-
555 antibody 
A-11008 1:5000 Life Technologies 
Alexa Fluor® Mouse-
647 antibody 
A-21236 1:500 Life Technologies 
 
Table 5: Staining used in Confocal analysis 
Staining  Dilution Supplier 
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Table 6: Inhibitors used for Western blot 
Inhibitors Concentration/ 
Quantity used in 
each well 
Catalogue no. Supplier 
BafA1  200 nM  B1793 Sigma 
MG132  10 µM  C2759 Sigma 
HBBS  
(Starvation Medium) 
    2 ml H8264 Sigma 
 




DpnI R0176L 20 000 U/ml New England Biolabs  
Agel R0552L 50 000 U/ml New England Biolabs  
Bbsl R3539 20 000 U/ml New England Biolabs  
 
Table 8: Plasmid constructs 
Plasmid Construct Description  Source 
pDest-EGFP-TRIM32 Mammalian expression vector for 
EGFP-tagged TRIM32 
(Overa et al., 2019) 
pDest-EGFP-TRIM32 
K50R 
Mammalian expression vector for 
GFP-TRIM32 with K50R mutation 
(Made in this work) 
pDest-EGFP-TRIM32 
K247R 
Mammalian expression vector for 
GFP-TRIM32 with K247R mutation 
(Made in this work) 
pDest-EGFP-TRIM32 
K401R 
Mammalian expression vector for 
GFP-TRIM32 with K401R mutation 
(Made in this work) 
pDest-EGFP-TRIM32 
K50R/401R 
Mammalian expression vector for 
GFP-TRIM32 with K50R/401R 
mutations 
(Made in this work) 
pDest-EGFP-TRIM32 
K50R/247R 
Mammalian expression vector for 
GFP-TRIM32 with K50R/247R 
mutations 
(Made in this work) 
pDest-EGFP-TRIM32 
K401R/K247R 
Mammalian expression vector for 
GFP-TRIM32 with K401R/K247R 
mutations 
(Made in this work) 
 




Mammalian expression vector for 
GFP-TRIM32 with 
K50R/401R/K247R mutations 
(Made in this work) 
pDest-mCherry-USP2 Mammalian expression vector for 
mCherry tagged USP2 
(Made in this work) 
pDONR-TRIM32 wild type Entry vector for TRIM32 (Overa et al., 2019) 
pDONR-TRIM32 K50R Entry vector K50R mutated TRIM32 (Made in this work) 
pDONR-TRIM32 K247R Entry vector K247R mutated 
TRIM32 
(Made in this work) 
pDONR-TRIM32 K401R Entry vector K401R mutated 
TRIM32 
(Made in this work) 
pX 458 CRISPR/Cas9  (Ran, Hsu, Wright, et al.,  
2013)  
 
Table 9: Reagents used for sequencing 
Reagents Description  Source 
Big dye DNA Sequencing Applied Biosystems 
6x Sequencing Buffer DNA Sequencing Applied Biosystems 
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3.2. General Methods 
 
3.2.1. Plasmid purification from E.coli 
The bacterial plasmid DNAs are extensively used as a cloning agent in DNA recombinant 
technology. A method used for extracting DNA plasmid from bacterial cells was developed and 
explained by Birnboim and Doly in 1979. The principle of this method is based on the selective 
alkaline denaturation of high molecular weight chromosomal DNA, whereas the covalently 
closed circular DNA remains double-stranded. At the time of n eutralization, the chromosomal 
DNA renatures again to form an insoluble clump, while plasmid DNA remains in the 
supernatant (Birnboim and Doly, 1979). 
In this method, the plasmid-containing cells are treated with sodium dodecyl sulfate (SDS), 
which diminish the cell wall and then NaOH is used to lyses the cells completely. Then the 
chromosomal DNA is denatured by turning conditions into alkaline pH value. Neutralization 
of lysate is obtained by using acidic sodium acetate, which results in renaturation of DNA 
leading to formation of aggregates in the form of an insoluble network. At the same time, 
protein-SDS complexes and high molecular weight of RNA precipitates due to the high 
concentration of sodium acetate. Thus, in this way most of the major contaminating 
macromolecules are co-precipitated and removed by simple centrifugation. The plasmid DNA 
or covalently closed circular (CCC) DNA stays in the supernatant and is recovered by binding 
to a column (Birnboim and Doly, 1979). 
Procedure of Plasmid Miniprep 
The method of plasmid miniprep were performed at room temperature and all centrifugation 
steps were performed at maximum speed of 13000 rpm in a tabletop centrifuge machine. The 
protocol of Gen Elute Plasmid Miniprep kit (Sigma, www.sigmaaldrich.com) have been 
followed. The following steps were performed during plasmid miniprep. 
1. Harvest and lysate bacteria 
The overnight bacterial culture of 1500 μl was centrifuged for 1 minute in eppendorf tube 
and the supernatant was removed. The cells were resuspended in 200 μl resuspension 
solution by pipetting and vortex in until the pellet was completely dissolved. Afterwards, 
200 μl lysis solution was added to the eppendorf tube and inverted gently 4-6 times to mix. 
This solution in the tube was left to clear for 5 minutes. 
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2. Preparation of cleared lysate 
350 μl neutralization solution was added to the tube and inverted this tube gently 4-6 times 
to mix completely. The debris was pelleted by centrifugation for 10 minutes.  
 
3. Preparation of binding column  
500 μl column preparation solution was added to the plasmid DNA binding column in a 
collection tube and centrifuged for 1 minute. The flow through was removed from tube. 
 
4. Binding of plasmid DNA to the column 
The cleared lysate from step 2 was transferred to the binding column and centrifuged for 1 
minute. The flow through was removed. 
 
5. Wash to remove contaminants 
750 μl wash solution was added to the column and centrifuged for 1 minute. The flow 
through was removed from tube. This tube was centrifuged again for 1 minute to dry the 
column. 
 
6. Eluted purified plasmid DNA  
The column was transferred to a clean eppendorf tube and 100 μl elution solution was added 
to the column and centrifuged for 1 minute. The eluted plasmid was stored at -20°C. 
 
3.2.2. Measurement of plasmid DNA concentration by Nanodrop 
The most commonly used instrument for the measurement of DNA concentration in a solution 
is the Nanodrop™ spectrophotometer (Thermo Scientific). The determination of the quality and 
quantity of DNA for this instrument have been facilitated by using a ratio of UV absorbance of 
260/280 nm (Brzobohata et al., 2017). Because a common nucleic acid sample will show a very 
distinctive profile normally in the range of 260/280 nm. To evaluate the sample quality 
precisely the ratios of 260/280 or 260/230 should be considered in combination along with the 
general spectral quality. Generally, perfect nucleic acids produce a 260/280 ratio of ~1.8 as well 
as a 260/280 ratio of ~2.0 for all DNA and RNA respectively. This ratio is totally dependent on 
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the pH value and ionic strength of that buffer, which is used to make both blank and sample 
measurements (Desjardins and Conklin, 2010). The Nanodrop Spectrophotometer allows a 
highly accurate analyses of only1 μl samples with significant reproducibility. Moreover, this 
instrument has the ability to measure samples with high concentration without dilution 
(tools.thermofisher.com). 
In this work, concentration and purity of eluted plasmid obtained from miniprep was measured 
by using a Nanodrop device ND-1000 spectrophotometer (Nanodrop Technologies/Thermo 
Fisher Scientific) in ng/μl. 
 
3.2.3. Gateway LR protocol (From ENTRY clone to DEST vector)  
The Gateway system is based onsite-specific recombination reactions, which allows the 
bacteriophage lambda (λ) to combine and edit itself in and out of a bacterial chromosome. 
Normally, these Gateway protocols and the recombination reactions are driven by two enzyme 
blends, which are called BP and LR clonase reactions. Once captured as an entry clone, a DNA 
fragment can be recombined into a various range of destination vectors that are expression 
vectors for special applications. The entry/donor vectors can be established by conventional 
cloning or by a BP reaction on DNA fragments containing attB sites. The BP reaction is 
catalyzed by the enzyme mix of BP Clonase II that consists of the phage integrase as well as 
the integration host factor (Karimi, Depicker, and Hilson, 2007; Liang et al., 2013). The LR 
reaction is catalyzed by the enzyme mix of LR Clonase II that consists of integrase, integration 
host factor as well as the phage excisionase (Figure 13). The LR reaction includes the 
recombination of an attL substrate (in an entry/donor clone) with an attR substrate (expression 
vector) to build an attB-containing expression clone (Karimi, Depicker, and Hilson, 2007; Park, 
Throop, and Labaer, 2015). 
 
 
Page 41 of 109 
 
                                            
Figure 13: The LR clonase mix is used to transfers the DNA fragment of interest, which are flanked 
by two attL sites in the entry clone vector (pENTR) that recombine with the corresponding attR sites of 
a destination vector (pDEST) carrying two attR sites. After recombination of the matching both the attL 
and attR sites, the DNA fragment of interest is inserted into a new expression clone (pEXPR) to produce 
attB in a new expression vector (pEXPR) and attP as a byproduct. The ccdB (control of cell death) gene 
is a standard Gateway cassette (attR1-ccdB-attR2) precedes the ORF coding for an enzyme (Obtained 
from Karimi, Depicker, and Hilson, 2007). 
 
Procedure 
For the conversion of pDONR to pDEST, 100ng pENTR (pDONR) plasmid, 150ng destination 
vector (pDEST - EGFP), 0.5 μl LR reaction mix and TE buffer up to 10 μl were mixed in an 
eppendorf tube. The tube was incubated at 25 °C for 2 hours. Afterwards, 1 μl proteinase K was 
added and incubated at 37 °C for 10 min. The sample was transformed into E.coli followed by 
plasmid miniprep and verified by restriction enzyme digestion and  agarose gel electrophoresis. 
 
3.2.4. Agarose gel electrophoresis 
Agarose gel electrophoresis is a simple and highly efficient method for separating, analyzing 
and purifying DNA fragments in the range of 0.5 to 25‐kb (Voytas, 2001). By using the method 
of agarose gel electrophoresis for separation of DNA fragments, the DNA fragments are loaded 
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into pre-cast wells in the agarose gel and then appropriate current applied. The DNA molecule 
is negatively charged due to the possession of phosphate backbone, thus when it is placed in an 
electric field these DNA fragments will move to the positively charged anode. the DNA has a 
systematic mass/charge ratio, so that DNA molecules are separated by size inside an agarose 
gel in a pattern such that the distance traveled is inversely proportional to the log value of its 
molecular weight. The principal model for DNA movement over an agarose gel is followed by 
"biased reputation model", whereby the prominent line moves forward and drags the rest of the 
molecule forward. The migration rate of a DNA molecule through an agarose gel is determined 
by the following factors. Size of the DNA molecule because larger molecules move more 
slowly due to greater frictional burden as well as they worm their way through the gel pores 
less efficiently compared than smaller molecules, type and concentration of agarose, voltage 
applied, DNA conformation, presence of DNA dye (GelRed) and electrophoresis buffer. When 
separation is done then staining with nucleic acid dye (Gel red) is performed and the DNA 
molecules can be visualized under UV light (Lee et al., 2012; Smith, 1993). 
GelRed is a new fluorescent nucleic acid stain, which is designed for the purpose of replacing 
ethidium bromide (EtBr) due to its highly toxic nature. GelRed facilitates the method of gel 
electrophoresis and other experimental methods, which mainly rely upon the fluorescence of 
stained DNA. When bound to DNA, GelRed shows the same absorption and emission spectra 
level, which is shown by EtBr (Crisafuli, Ramos, and Rocha, 2015). However, according to its 
Safety Report from Ames test, it is shown as non‐mutagenic. For example, GelRed fails to enter 
the HeLa cells after 30 min treatment as well as it also produces negative results for the mouse 
spermatocyte chromosomal aberration test (Sayas, Garcia-Lopez, and Serrano, 2015). 
Procedure 
1 % agarose gel was prepared by mixing 1 g of agarose with 5 ml of 20x minigel buffer and 94 
ml of dH2O. The solution was completely mixed by boiling in microwave oven. This solution 
was poured slowly into the casting frame along with insertion of a comb for producing wells. 
The solution was left for polymerization at room temperature for approximately 20-30 minutes.  
The comb was removed slowly before placing the gel in a tray. Minigel buffer was added until 
covering of the gel. In other side, the calculated amount of DNA samples was mixed with TE 
buffer and 6xT gel loading buffer before employing into the wells along with the ladder (1 kb). 
The current wires were connected with the tray for applying 90 V current to the gel for 1 hour. 
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Afterwards, the gel was stained in GelRed for 20 minutes. The DNA bands and 1 kb ladder 
were visualized on the gel by exposing to the UV light at 302 nm using a UV transilluminator. 
Finally, images of the gel were obtained by using Multi-Cod Digital imaging system. 
 
3.2.5. Restriction enzyme digestion 
The restriction of DNA was first discovered and explained by Arber and Dussoix in 1962 during 
the analyzing of the molecular mechanisms of host-controlled modifications of bacteriophage. 
(Arber and Linn, 1969). Restriction enzymes are very useful due to recognition of specific 
nucleotide sequences and provide a very specific cleavage of DNA (Roberts, 2005; F, Micheli, 
and Camilloni, 2019).  
Procedure 
The quantity of 100 ng plasmid DNA was mixed with 1μl 10x cutting buffer. Afterwards, a 
quantity of 0.5μl of each desired restriction enzyme (EcoRI or Bsr GI) was mixed along with 
dH2O to make a total volume of 10 μl in an Eppendorf tube. This was mixed carefully and left 
for incubation at 37 °C for 1 hour in water bath. Finally, after incubation 2 μl 6xT loading buffer 
was added and the sample analyzed by agarose gel electrophoresis. 
 
3.2.6. Preparation of bacterial Freeze Stocks 
Freezer stocks of bacterial cultures is a way to store E. coli transformed with a specific plasmid 
for later use. 1200 μl of the bacterial overnight culture was mixed with 300 μl 50% glycerol in 
a 2 ml Cryo tube and stored at -70 oC. 
 
3.2.7. Site-directed mutagenesis 
Quick change site directed mutagenesis (developed by STRATAGENE) is a simple and rapid 
procedure that includes PCR, DpnI digestion and overlap extension. The important point of this 
approach is the use of overlap extension to design a circular DNA plasmid with mutations and 
this all obtained without the use of phosphorylated primers or ligase reactions. The new DNA 
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is synthesized with nicks between the 3' ends of the synthesized DNA as well as the 5' ends of 
the first pair of primers during the first round of PCR. Finally, a new pair of mutagenic 
oligonucleotides leads to the combination of the two DNA sections that anneal together with 
the overlap sequence inside the two primers during successive rounds of PCR. This new 
mutated molecule also includes nicks at various positions when compared with those constructs 
in the first turn of PCR that had been "repaired" by overlap extension. By using this method, 
mutations can be introduced successfully. Afterwards, the circular DNA is transformed into E. 
coli cells, where the circular plasmid is ligated (Forloni, Liu, and Wajapeyee, 2019). 
 
3.2.7.1. Polymerase chain reaction 
The polymerase chain reaction (PCR) is an important tool, which is used to amplify a specific 
DNA sequence. This method was developed by Kary Mullis in 1983 (Mullis and Faloona, 
1987). The PCR reaction can be performed by using a source of DNA obtained from variety of 
tissues and organisms. PCR facilitate to generate several copies of DNA from a very small 
amount. PCR based DNA amplification is today used both as a diagnostic tool in the clinic, and 
in conventional laboratory methods (Garibyan and Avashia, 2013).  
Procedure 
The following reagents which were mixed in a PCR tube for running in a PCR reaction. 
• 0.2 μl       Forward primer (10 mM) 
• 0.2 μl       Reverse primer (10 mM) 
• 0.1 μl       Template DNA (20-30 ng) 
•  2.5 μl       PFU reaction buffer (10x) 
•  1 μl          dNTP mix (10 mM) 
•  1 μl          DMSO (Dimethyl sulfoxide) 
•  0.5 μl       Pfu DNA Polymerase  
•  dH2O to 25 μl         
 
 
The following PCR program for site-directed mutagenesis was used: 
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1. 95 °C      30 sec (Initial denaturing) 
2. 95 °C      30 sec (Denaturation) 
3. 55 °C      1 min (Annealing) 
4. 68 °C      2 min per kb (Elongation) 
5. Go back to step 2 for 20 times 
6. 68 °C      5 min (Final elongation) 
7. 4 °C ∞  
To remove template DNA, 0.8 μl DpnI was added and left for incubation at 37 °C in water bath 
for 1 hour. DpnI restriction enzyme requires methylation at their recognition sites in order to 
efficiently cleave DNA. Therefore, it will cleave only the template plasmid, and not the mutated 
plasmids generated by PCR (blog.addgene.org).  
 
3.2.8. Transformation of competent E. coli (DH5α) 
The artificial method of DNA transfer into Escherichia coli was first demonstrated by Mandel 
and Higa in1970 (Hanahan, 1983). The transformation of bacteria involves two general phases 
such as DNA binding to the cell surface, which is followed by uptake of that DNA across the 
cell envelope into the cytoplasm and establishment as well as expression of that DNA as a stable 
genetic element in the cell (Hanahan, 1983; Panja et al., 2006). The naturally occurring bacterial 
transformation are found in various bacterial genus. For example, Micrococcus, Bacillus and 
Haemophilus organisms shows proteins on their outer surface. The main function of this protein 
is to bind to DNA in their environment and transfer to the cell. However, it is not common for 
most of the bacteria to naturally take up DNA from the environment. But when certain artificial 
conditions are subjected to most bacteria then they become able to take up free DNA and the 
cells in such artificial state are indicated as competent. E. coli has grown and developed into a 
universal host organism for the purpose of both DNA molecular cloning as well as for a various 
set of analysis that involve cloned genes (Panja et al., 2006). The competence can be developed 
in E. coli by using different methods. E. coli DH5α used in this study is chemically competent. 
This chemical method involves the treating of bacteria with bacteriophage “λ” DNA in the 
presence of Ca2+ ions by suspending the cells in ice-cold of CaCl2 such as 50–100 mM and then 
followed by a brief heat shock at 42 °C. This method is known as the “calcium chloride (CaCl2)” 
method and it is used by our lab as well (Panja et al., 2006; Chan et al., 2013). 
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Procedure 
The chemically competent E. coli DH5α cells were thawed on ice around 15-30 minutes. The 
quantity of 80 μl E. coli (DH5α) cells were added in an eppendorf tube. Then an appropriate 
amount of DNA plasmid was mixed into the tube. This mixture was incubated for 20 minutes 
on ice. After the incubation, the transformation mixture was heat shocked at 37 °C for 2 minutes 
in water bath. Afterwards, there was added 250 μl SOC media and left for incubation at 37 °C 
with 150 rpm shaking for 1 hour. Finally, the incubated mixture was plated by 100-200 μl onto 
LB plates with ampicillin or kanamycin (Table 1) depending on the plasmid. The plate was left 
for incubation overnight at 37 °C. 
 
3.2.9. Sanger sequencing 
The first sequencing for a complete genome was published by the Nobel Prize winner in 
Chemistry named Frederick Sanger. Today, the Sanger sequencing method is still broadly used 
all over the world and is mainly based upon the use of dideoxynucleotides (ddNTPs) that have 
been used to block DNA polymerization. Basically, the dideoxynucleotides are similar to the 
deoxynucleotides (dNTPs). The only variation is that the ddNTPs require a hydroxyl group (-
OH) on the position of the third carbon of the ribose and this also induces the enzyme to cease 
the polymerization, since it is not capable to find the chemical group to attach to the next 
nucleotide. The reaction which is prepared by the DNA polymerase along with a combination 
of dNTPs as well as ddNTPs, so that at all extensions of a nucleotide, the enzyme can absorb 
either of them randomly (Figure 14) (Garrido-Cardenas et al., 2017).    
In the Big Dye (Applied Biosystem) DNA sequencing kit used here, each ddNTPs is tagged by 
a specific fluorophore molecule, so that every time one of them is integrated, the produced 
molecule will discharge a specific signal that will notify on the last integrated nucleotide. In 
this manner, after a sufficient number of cycles of amplification, the number of molecules will 
be equivalent to the number of nucleotides that incorporated into the DNA fragment to be 
sequenced. Later a capillary electrophoresis is carrying out along with these molecules. As a 
result, they will be arranged according to increasing order of molecular mass in which each 
molecule can be detected by the fluorophore, which is joined to the reciprocal ddNTPs 
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terminator of the reaction. The detection method is carried out by a device of Charge-Coupled 
Device (CCD) spectral detector (Garrido-Cardenas et al., 2017). 
In this work, the Big dye V 3.1 DNA sequencing kit (Applied Biosystem) was used. The 
sequencing reactions was sent to our in-house sequencing lab, where the instrument of ABI 
PRISM 3130x1 Genetic analyzer (Applied Biosystem) was used for the determination of the 
DNA sequence. 
Figure 14: This figure shows the sanger dideoxy sequencing method or chain termination enzymatic 
method. The fluorescence-labeled ddNTPs have been used to block DNA amplification, which is also 




The following reagents were mixed in a 0.2 ml PCR tube on ice. 
• 1 μl      Plasmid (200-300ng) 
• 1 μl      Primer (10μM) 
• 1 μl      Big dye V 3.1(Applied Biosystem)    
• 2 μl      5x Sequencing buffer (Applied Biosystem)  
• 5 μl      dH2O (Total volume of 10 μl) 
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The PCR program for sequencing was: 
1. 96°C      1 min 
2. 96°C      30 sec 
3. 50°C      15 sec 
4. 60°C        4 min  
5. Go back to step 2 for 34 times 
6. 4°C  ∞  
 
The obtained sequencing result was further analyzed by Chromas software sequence 
(http://technelysium.com.au/wp/chromas/) and NCBI BLAST (https://blast.ncbi.nlm.nih.gov). 
 
3.2.10. Mammalian cell culture 
Mammalian cells were grown in a 5% humidified CO2 incubator at 37°C. All the solutions 
which were used for growing of cells cultures were preheated to 37°C. The HeLa cells (ATCC, 
CCL2), MCF-7 breast cancer cell lines (ATCC, HTB-22) and HEK293 FlpIn TRIM32 KO cells 
(ATCC, CRL-1573) (Overa et al., 2019) cells were grown in MEM with 100 U/ml penicillin 
and 100 g/ml streptomycin and 10% FCS solution mixture. The MDA-MB-231(ATCC, HTB-
26) breast cancer cell line was grown in RPMI with 100 U/ml penicillin and 100 g/ml 
streptomycin and 10% FCS solution mixture. Similarly, C2C12 mouse myoblast (ATCC, CRL-
1772) cell line and the H9c2 rat myoblast (ATCC, CRL-1446) cell line were grown in DMEM 
with 100 U/ml penicillin and 100 g/ml streptomycin and 10% FCS solution mixture.   
3.2.10.1. Splitting and counting of cells  
The cells in the cultures have the capability to grow and double in number after every 24 hours. 
When the cells have grown confluent contact inhibition will make them difficult to transfect 
and result in stop of growth, detachment and dead. 
Therefore, there is need to split the cells when they are confluent. All the mammalian cells used 
in this lab work were divided and diluted 1:2, 1:4, 1:6 or 1:8 depending on when the next 
splitting or transfection event was going to take place.  All the mammalian cells were grown in 
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a filter capped flask having a culture area of 75 cm2 (T75) or 175 cm2 (T175) (Thermo Fisher 
scientific). 
Procedure 
When the cells were confluent, the cell medium removed by suction and these cells in flask 
(T75 or T175) were washed by 5-10 ml of 1xPBS solution. After washing, 0.5-1ml trypsin was 
added and evenly distributed over the cells, incubated for 1-2 minute until the cells had 
detached. Afterwards, culture medium was added to inactivate the trypsin. A small volume of 
these cells culture solutions, depending on when the next splitting or transfection event take 
place were transferred to a new flask, 5-10 ml fresh media added, left in incubator for next time 
use. 
 
3.2.11. Transfection of mammalian cells  
Transfection of mammalian cells is the uptake of foreign DNA and is a widely used technique 
(Cervera and Kamen, 2018). Eukaryotic cells show the capability to take up external DNA 
under various suitable conditions and this DNA becomes localized in the nucleus. This 
phenomenon has been used to get both transient and stable expression of different genes 
(Felgner et al., 1987). The transient transfection has been performed by various kinds of DNA 
transfection reagents such as calcium phosphate, cationic lipids and cationic polymers (Cervera 
and Kamen, 2018). An extensive range of cationic lipid reagents for the purpose of lipofection 
are manufactured, marketed as perfect for various types of cells and diverse types of nucleic 
acids such as co-transfection of both RNA and DNA (Marwick and Hardingham, 2017). 
Cationic lipids such as Lipofectamine or METAFECTENE® PRO (Biontex) are very efficient 
and useful in terms of transfection efficiency (Cervera and Kamen, 2018). In this technique, 
Lipofection are used to introduce DNA or RNA into the cells by producing a liposome that 
contain positively charged lipids by encircling the negatively charged nucleic acids. These 
liposomes are ready to combine with cell membranes allowing the access of nucleic acids inside 
the cell (Figure 15) (Marwick and Hardingham, 2017). 
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Figure 15: This figure shows the complete mechanism in which lipofection promotes entry of nucleic 
acid into the mammalian cells. The lipid membrane is surrounding the DNA and merge with the cell 
membrane by releasing the DNA into the cells (Obtained from Felgner and Ringold, 1989). 
 
Procedure 
The number of mammalian cells were counted by using a drop of the cells in the Büchner 
chamber and counted under a microscope. The number of counted cells in a Büchner square 
was multiplied with 104 value to obtain the number of cells per ml solution. Alternatively, the 
mammalian cells were counted in TC20 Automatic cell counter. An appropriate number of cells 
for transfection (300,000 cells per well in 6-well dish) were poured into each well for 
transfection along with fresh culture media of MEM+10% FCS or RPMI+ 10% FCS(2 ml in 
each well in a 6 -well dish) and left for incubation for 24 hours. 
When the cells were ready for transfection, a mixture for each well were prepared in an 
eppendorf tube by mixing 150 μl MEM or RPMI media without antibiotic, plasmid DNA 
(1000ng), 2.5 μl transfection agent (METAFECTENE® PRO (Biontex)) and left for 20 minutes 
incubation at room temperature. The growth media of cell wells was changed with 2 ml of fresh 
growth media in each well. After 20 minutes the transfection mix was added to each well. The 
cells were left for transfection in the incubator for 24 hours. Next day, the cells were checked 
 
Page 51 of 109 
 
under a fluorescence microscope (LECIA CTR 6000) for transfection efficiency (number of 
cells expressing GFP). When a good transfection efficiency was obtained then the cells are 
ready for harvesting.  
3.2.11.1. Treatment with different inhibitors  
The transfected cells were treated with Bafilomycin A1 (0.2 μM) or MG132 (20 μM) inhibitors 
along with fresh culture media (10% FCS + MEM) or starvation media (HBSS). The MG132 
is a powerful, reversible and cell-permeable proteasome inhibitor whereas, Bafilomycin A1 
inhibits the lysosome. The cells were treated for 3 hours before harvested by 2x SDS loading 
buffer with 200mM DTT freshly added. Alternatively, the cells were also treated with 
Bafilomycin A1 (0.1 μM) or MG132 (5 μM) for 24 hours. 
 
3.2.12. SDS- PAGE  
Sodium Dodecyl Sulfate Polyacrylamide Electrophoresis (SDS-PAGE) is widely used 
technique for analyzing proteins in a mixture (Smith, 1984). This method is also used for 
determining the molecular weight and analysis of proteins, which are isolated by 
immunoprecipitation of various cell extracts (Trieu and Targoff, 2019). The percentage of 
polyacrylamide, which is used in the gel along with the buffer system will control the proteins 
mobility through the gel when current is applied. In this technique the proteins are reacted with 
the anionic detergent SDS. The normal size of the target protein is used to select the correct gel 
and buffer system to produce optimum level of separation and resolution. The protein samples 
are supported by dye indicator and glycerol in the sample loading buffer. When the current is 
applied, proteins move through the gel and are separated by charge. The charge of the SDS-
protein complex is roughly proportional to protein size. A protein standard is included in one 
well/lane, which is composed of a pool of proteins with known molecular weights (Smith, 1984; 
Hnasko and Hnasko, 2015). 
Normally, the electrophoresis in SDS-PAGE is run in a discontinuous buffer system provided 
with two gels such as a lower buffer level, which is used for the separating gel and an upper 
buffer level, which is used for the stacking gel/concentrating gel. Both gels contain SDS but 
with various ionic strength and pH level. The staking gel have the capability to concentrates the 
sample because it does not permit the movement of the SDS-peptide complexes at its own 
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speed, until they move to the separating gel where they are segregated and separated according 
to their size. This method allows the separation of comparatively large volumes of samples 
without falling resolution (Garcia-Solaesa and Abad, 2016).   
Procedure 
Harvesting of cells for Western Blotting 
The growth medium was removed, and the cells washed with 1x PBS two times. 80 μl of 2x 
SDS loading buffer with 20 % DTT was dropped to each well in a 6-well dish. The cells were 
scratched from the wells and cell lysates were collected in Eppendorf tubes. These lysate cells 
were boiled for 10 minutes at 100°C and spun down. The supernatants were now ready for 
loading on an SDS-PAGE. 
Casting and loading of SDS-PAGE 
The SDS-PAGE was prepared by collecting two plates, one glass and one plastic which were 
separated by spacers and mounted in a gel caster. The components of 8% separating gel was 
mixed (see Table 2) and poured between the fixed plates until 2/3 filled. A small amount of 
water was added on the top side of separating gel to keep the gel straight. The gel was left for 
20 minutes until polymerization. Afterwards, 4 % concentrating gel was mixed (see Table 2) 
and poured on the upper side of separating gel after removal of water.  A piece of comb was 
placed in this concentrating gel for creation of wells and the gel was left again for 20 minutes 
until polymerization. The prepared gel was mounted in an electrophoresis apparatus. The comb 
was removed from the gel and electrophoresis buffer was added to the vertical and bottom side 
reservoirs. A quantity of 5 μl biotinylated protein ladder and 5 μl blue pre-stained ladder were 
mixed and this ladder mix was loaded in the gel. Afterwards, cell lysates were loaded onto the 
wells and the gel was left for 1-2 hours running at 26 mA along with water cooling until the 
blue staining reached at bottom line. 
 
3.2.13. Western blot 
Western blotting or protein immunoblotting is a widely used technique in which an individual 
protein is visualized in the middle of thousands of other proteins in a sample. This technique 
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uses SDS-PAGE method to separate proteins in the sample on the basis of size (Roy et al., 
2019). This technique was developed in 1979 by several groups independently and was later 
named ‘Western blotting’ due to its correlation to southern and northern blotting (Towbin, 
1998). This method is based upon using antibody-based examinations to gather important 
information related to target proteins from complex samples (Najafov and Hoxhaj, 2017). The 
separated proteins from SDS-PAGE are transferred and immobilized onto a PVDF 
(polyvinylidene difluoride) or nitrocellulose membrane. The membrane is washed, blocked as 
well as incubated with an analyte-specific primary antibody. There are two simple approaches 
involving the use of a direct reporter-labeled primary antibody or a reporter-labeled secondary 
antibody, which are directed against the present species of the primary antibody. The reporter 
conjugated to the antibody can be different. For example, an enzyme that produces a reaction 
product with color or when exposed to a substrate, a luminescent signal was produced at the 
place of antigen-antibody binding (Hnasko and Hnasko, 2015; Roy et al., 2019). Western 
blotting can be quantitative or semiquantitative, which is depending on the type of reagents 
used (Najafov and Hoxhaj, 2017).  
It is a regular method that is mainly adopted in the field of molecular biology, biochemistry and 
cell biology with a vast number of applications. This method can be facilitated to get valuable 
information about protein quantity, its molecular weight as well as post-translational 
modifications. Western blotting is a very sensitive method, which is due to the high affinities 
of antibody approaching their epitopes as well as due to amplificatory nature (Najafov and 
Hoxhaj, 2017). Western blotting can identify target proteins as low as 1 ng in concentration due 
to its high-resolution quantity of gel electrophoresis as well as strong sensitivity and specificity 
provided by the immunoassay (Roy et al., 2019). Even picogram amounts of target proteins can 
be observed (Najafov and Hoxhaj, 2017).  
Procedure 
A nitrocellulose blotting membrane (Sigma, GE10600003) along with 6 pieces of filter paper 
was prepared with the same sizes as separating gel 6.5 x 8.5 cm. A sandwich was made by 
placing sponge at the bottom followed by three filter paper soaked by 1x Transfer buffer (Table 
2), the membrane, the separating gel and finally remaining three filter papers soaked by 1x 
Transfer buffer. A roller was used to avoid bubbling in the sandwich. The sandwich was locked 
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in a holder and placed in a blotting chamber (Trans-Blot® Turbo™ Transfer System BIO-
RAD). A current of 25 volts was applied for 7 minutes to transfer the proteins from the gel to 
the membrane. 
The blotting membrane was removed from the sandwich and left for 5 minutes with 5% ponceau 
staining solution and washed with water. This membrane was washed again for 5 minutes by 
soaking in 1xTBS-T solution at room temperature with shaking. The membrane was blocked 
by soaking into 5% blocking milk solution at room temperature by shaking for 30 minutes. A 
quantity of 1.5 ml 5% blocking milk was mixed with primary antibody (Table 4) in a 50 ml 
tube. The blotting membrane was transferred to the 50 ml tube and left for incubation on 
rotating roller for ON (overnight) at 4°C. Afterwards, the membrane was washed in 1xTBS-T 
solution three times for 10 minutes each. A quantity of 1.5 ml with 5% blocking milk was mixed 
with secondary antibody (Table 4) and ladder antibody (HRP-conjugated anti-biotin antibody) 
in a 50 ml tube. The blotting membrane was again transferred to the 50 ml tube and left for 
incubation on rotating roller for 1 hour at RT. The membrane was washed in 1xTBS-T solution 
three times for 10 minutes each. Finally, the membrane was wrapped in a plastic foil dropped 
by chemiluminescent peroxidase substrate (Sigma). The membrane signals were detected by 
Image Quant Las 4000 (GE Lifesciences). 
 
3.2.14. Confocal Microscopy 
The most important and diverse application of confocal microscopy in the field of biomedical 
sciences is the use for imaging either in the form of fixed or living cells that have usually 
been tagged with one or more kinds of fluorescent probes (Paddock, 1999). These confocal 
instruments have the capability of revealing fluorescence emissions in the ranges of 400 to 700 
nm. This also provide to covers a broad range of frequently available fluorescent probes. The 
fluorophores consist of various synthetic fluorochromes such as the Alexa dyes and quantum 
dots, and the naturally occurring fluorescent proteins, which include green fluorescent protein 
(GFP) and its color mutants such as CFP and YFP (Paddock, 2014). GFP is a spontaneously 
fluorescent protein, which was isolated from the jellyfish Aequorea victoria (Yang, Moss, and 
Phillips, 1996; Heim, Cubitt, and Tsien, 1995). GFP can provide its role as a protein tag and its 
expression can be further used to monitor gene expression as well as protein localization in 
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living organisms. Exogenous GFP is highly expressed in mammalian cells and its fluorescence 
is generally dispersed throughout the cytoplasm and nucleus. GFP consists of 238 amino acids 
and it absorbs blue light at 395 nm and emits green light with emission peak at 509 nm (Yang, 
Moss, and Phillips, 1996; Chalfie et al., 1994). Enhanced Green Fluorescent Protein (EGFP) is 
a mutant from wild type GFP with an excitation at 490 nm (Masters et al., 2018).  
The first confocal microscope was invented by Minsky in 1955 (Prydal and Dilly, 1998). The 
Confocal laser scanning microscopy is the most suitable method, which is used for visualization 
of intracellular co-localization of proteins found in intact cells. CLSM also offers important 
advantages for examining of subcellular localization of proteins when compared with other 
conventional fluorescence microscopy (Miyashita, 2004). The fluorophores have been designed 
according to the specific target and helpful to analyze subcellular structures of the cytoplasm, 
mitochondria, nucleus and co-localization of proteins with multicolor labeling. The laser part 
of fluorescence confocal microscopy is provided by an excitation light at a wavelength that will 
also excite a fluorophore of a specific type. The target tissue hits by the excitation laser to 
produces high intensities of fluorescence at a precise focal point. There is only light coming 
from the focal plane that is detected because the light approaching from additional planes 
cannot pass over the pinhole. Both the laser light or the excitation beam and the resultant 
emission fluorescence light pass over the identical objective of a special mirror, which is known 
as dichroic mirror. This mirror also reflects the incoming higher-energy with shorter-
wavelength laser light but admits the lower-energy with higher-wavelength of fluorescent light 
to move through the light detector (Figure 16). In fluorescence confocal microscopy, a pinhole 
is also used to get rid of scattered light. Finally, the light is collected from an extremely focused 
point and the images of the scanned specimen can then be reorganize point by point. (Miyashita, 
2004; Nwaneshiudu et al., 2012; Foldes-Papp, Demel, and Tilz, 2003). 
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Figure 16: The simplified view of confocal microscopy along with detector, dichroic mirror and lenses 
(Obtained from Nwaneshiudu et al., 2012). 
 
3.2.14.1. Seeding of cells in 8-well chamber for confocal microscopy 
The number of HEK293 FlpIn TRIM32 KO cells were counted in TC20 automatic cell counter 
cell and calculated the correct number of cells for transfection (4000 cells per well) in 8-well 
dish (NUNC#155411). The cells were poured into each well for transfection along with 0.5 ml 
fresh culture media and left for incubation for 24 hours. A mixture for each well were prepared 
in eppendorf tubes by mixing 25 μl MEM media without antibiotic, plasmid DNA (100 ng), 
0.5μ l transfection reagent (Trans IT, Mirus) and left for 15 minutes incubation at RT.  
The growth media was changed by 0.5 ml of fresh growth media of MEM+10% FCS in each 
well. The transfection mix was added dropwise to the wells. The cells were left for transfection 
in the incubator for 24 hours before fixation, immunostaining and analyses by fluorescence 
confocal microscopy. 
3.2.14.2. Cell fixation and immunostaining 
The cell media was removed and 250 μl of 4% Fomaldehyde (GH) was added and cells 
incubated 15 min at RT to fixate the cells. Afterwards, the cells were washed two times by 1x 
PBS. The cells were permeabilized by adding 500 μl methanol and left for incubation for 5 
minutes at RT before washed two times by 1x PBS. The cells were blocked by 5% Bovine 
serum albumin (BSA) in PBS for 30 minutes at RT. 
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The primary antibodies anti-GM130 and anti- p62 were diluted in 1% BSA (Table 4). This 
primary antibody mixture of 125 μl quantity was added into each well and left for incubation 
for 1 hour at RT. Afterwards, the cells were washed 3 times with 1x PBS before secondary 
antibodies treatment. The different secondary antibodies Alexa Rabbit-555 (Anti-rabbit) and 
Alexa Mouse-647 (Anti-mouse) along with DNA stain DAPI were prepared. This secondary 
antibody mixture of 125 μl quantity was added into each well and left for incubation for 1 hour, 
in dark at RT. Afterwards, the cells were washed 2 times with 1x PBS, and the cells were 
covered by 250 μl 1x PBS for further confocal analysis. 
3.2.14.3. Fluorescence Confocal Microscopy 
The confocal analysis of 8-well dish was performed by taking confocal images using a 40× NA 
1.2 water immersion objective on an LSM780/LSM800 system. There are 4 images per 
condition, each containing 10-20 cells, were analyzed by using the ZEN software (Zeiss). Each 
image includes 10-20 cells. 
 
3.3. Generation of knock-out cells by using CRISPR/Cas9  
This CRISPR/ Cas9 is a gene-editing technology, which mainly involves two types of important 
components, a guide RNA component or CRISPR RNA (crRNA), which is used to match a 
required target gene and Cas9 (CRISPR-associated protein 9), which is an endonuclease. The 
CRISPR RNA (crRNA) can be used to manage Cas9 to cut DNA and produce double-strand 
breaks at the position of specific target sites. The following cellular DNA repair process drives 
to desired insertions, deletions and replacements at the position of target sites. The specificity 
of the CRISPR/Cas9-mediated DNA cleavage desires target sequences corresponding crRNA 
and a protospacer neighboring motif (Ran, Hsu, Wright, et al., 2013; Redman et al., 2016; 
Zhang, Wen, and Guo, 2014). The Cas9 is guided by a small RNAs through Watson-Crick base 
pairing with the target DNA (Figure 17) (Ran, Hsu, Wright, et al., 2013). For example, by 
constructing a 20-nucleotide region, which is complementary to a DNA sequence of interest in 
the sgRNA. The Cas9 can be proposed at any genomic locus with a relevant PAM (proto-spacer 
adjacent motif) sequence. After the tracking and cleavage of DNA, the repair mechanisms can 
cause insertion and deletion mutations, which may generate a knock-out (Lentsch et al., 2019).   
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Figure 17: The diagrammatic representation of the RNA-guided Cas9 nuclease is shown. 
The Cas9 nuclease obtained from S. pyogenes (in yellow) is targeted to genomic DNA (such as human 
EMX1 locus) by using an sgRNA, which is consisting of a 20-nt guide sequence (blue) and a scaffold 
(red). The guide sequence pairs with the DNA target (blue bar shown on the top strand) directly upstream 
of a required 5′-NGG adjoining motif (PAM shown pink). The Cas9 mediates a DSB of ~3 bp is crucial 
for the PAM (red triangle) (Obtained from Ran, Hsu, Wright, et al., 2013). 
 
Methods performed to establish CRISPR/Cas9 mediated 
knock out cells 
The CRISPR/Cas9 system was used to generate a knockout cell line for TRIM32. The knockout 
cell line was generated as described by Ran, Hsu, Wright, et al., (2013). 
3.3.1. Determination of Cas9 target sites in gene of interest and order 
Oligos 
For determination of target sites in gene of interest, the online CRISPR Design tool software 
CHOPCHOP (https://chopchop.cbu.uib.no/) that takes an input sequence and identifies suitable 
target sites was used. We chose the two target sites sequences with top scores for mouse and 
rat TRIM32 genes. 
Mouse Target T1:  5’-CACCGATACGATAGTTGCCCCGGT-3’ 
              5’-AAACACCGGGGCAACTATCGTATC-3’ 
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Mouse Target T2: 5’-CACCGTGCTCGGGGCGACCTCATTG-3’ 
           5’-AAACCAATGAGGTCGCCCCGAGCAC-3’  
Rat Target T1:  5’-CACCGAAGATTTCCGCTGCATCGC-3’ 
            5’-AAACGCGATGCAGCGGAAATCTTC-3’ 
Rat Target T2:   5’-CACCTACAGCGTCCTTATTCGAGA-3’ 
            5’-AAACTCTCGAATAAGGACGCTGTA-3’ 
 
The oligos were ordered from Thermo fisher. 
3.3.1.1. Phosphorylation and annealing of Oligoes 
The top and bottom strands of oligos were resuspended in dH2O to a final concentration of      
100 μM. The mixture for phosphorylation and annealing of sgRNA oligos were prepared by 
mixing the following contents in an Eppendorf tube. 
1 μl Oligo 1 (100 μM) 
1 μl Oligo 2 (100 μM) 
1 μl 10x T4 DNA ligase Buffer (NEB) 
1 μl T4 Polynucleotide kinase (NEB) 
Total: dH2O to 10 μl          
The sample was incubated in a PCR machine with the following program.  
            37°C      30 min (Phosphorylation) 
95°C       5 min (Denaturation)  
Temperature ramping down from 95°C to 25°C (Annealing).   
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3.3.1.2. Linearisation and Ligation in one step 
In this step, the phosphorylated and annealed oligoes were inserted in the pX458 plasmid 
established by Ran, Hsu, Wright, et al., (2013), which encodes the Cas9 endonuclease and GFP. 
1 μl 10X NEB2 buffer 
1 μl T4 DNA ligase Buffer (NEB) 
1 μl annealed oligo (diluted 1:200 in dH2O)   
300 ng pX458 plasmid 
0.5 μl Bbsl 
0.5 μl T4 DNA ligase (NEB) 
Total: dH2O to 10 μl         
The mix was incubated in a PCR machine with the following program.  
1. 37°C      20 min 
2. 16°C      15 min  
3. 37°C      10 min 
4. 55°C      15 min  
5. 4°C  ∞  
Step 1 and 2 are repeated 3X. 
 
3.3.2. Transformation of E.coli (DH5α) 
50 μl of the ligation mix was transformed into 50 μl of competent E.coli DH5α. The correct 
insertion of oligoes into the pX458 plasmid was verified by plasmid miniprep, restriction 
enzyme digestion, agarose gel electrophoresis and DNA sequencing using the U6 primer. All 
these methods are described above.   
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3.3.3. DNA Precipitation 
DNA precipitation of plasmids was done to purify the plasmids to increase transfection 
efficiency. DNA precipitation of the CRISPR pX458 plasmids with inserted sgRNA sequences 
pX458- m(mouse) TRIM32 (T1), pX458-mTRIM32 (T2), Px458-rat TRIM32 (T1) was 
performed. 80μl plasmid was mixed with 3M NaOAc pH 5.2 (1:10 vol). This mixture was 
mixed with 2 vol of 96% EtOH. Afterwards, the mixture was vortex for 10 seconds and left for 
incubation at RT for 20 minutes. After incubation, the mixture was centrifuged for 30 minutes 
at maximum speed. The supernatant was removed, and the pellet washed with 200μl 70% EtOH 
and centrifuged for 10 minutes at maximum speed. The pellet was dried before it was dissolved 
in 50 μl elution solution. The concentration and purity of the precipitated plasmid were 
measured by using a Nanodrop device (ND-100 spectrophotometer). 
 
3.3.4. Transfection of mouse myoblast (C2C12) and rat myoblast 
(H9c2) cells 
The transfection of mouse myoblast (C2C12) and rat myoblast (H9c2) cells with transfection 
agent METAFECTENE® PRO (Biontex) were performed in a similar way as explained above. 
 
3.3.5. Sorting of cells by flow cytometer 
One day post transfection the efficiency of the transfection was measured by fluorescence 
microscopy analysis of EGFP expression in the cells. Wells where the number of transfected 
cells was more than 35 % were harvested by trypsination, resuspended and filtered to ensure 
only single cells in the harvested solution. Thereafter, transfected cells were sorted into 96-well 
dish by using a cell sorter FACSAria cell sorter running FACSDiva software version 5.0 (BD 
Biosciences) in which the blue laser for excitation of GFP used. The GFP fluorescence was 
collected through a 530/30 nm bandpass filter in the E detector (Overa et al., 2019). The sorter 
picks out the green cells in the solution and seeds one green cells in each well of the 96-well 
dish. Before sorting the 96-well dish was poured by 100 μl DMEM+20% FCS into to each well.  
The 96 well dishes were incubated for nearly 3 weeks in the cell incubator. Medium was 
changed once a week, and the wells frequently investigated for cell growth.  
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When colonies of cells were detected by microscopy of the wells, the cells were detached by 
trypsination and transferred to a well in a 24-well dish. Each cell clone was given a specific 
number, and care was taken not to cross-contaminate the cell cultures. When the cells in the 
24-well dishes were grown to confluence, the cells were trypsinated and seeded into two wells 
in a 12-well dish. s and. One well was later harvested in 50 μl 2XSDS+20% DTT for Western 
Blotting while the other wells were expanded in a cell culture flask for further work and for 
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4. Results 
Previous mass spectrometric (MS) analysis of immunoprecipitated EGFP-TRIM32 from 
HEK293 FlpIn cells (Overa et al., 2019) identified three lysines that were ubiquitinated or 
acetylated in cells expressing EGFP-TRIM32 wild type, but not in cell expressing the 
LGMD2H disease mutant EGFP-TRIM32 D487N that is unable to undergo self-ubiquitination. 
These lysines were K50, K247 and K401. Bioinformatic analysis using the Phosphosite Plus 
software (www.phosphosite.org) confirmed that these lysines are potential targets for 
ubiquitination and acetylation (Figure 18). 
Figure 18: MS data analysis of TRIM32 is shown. The yellow points show ubiquitinated/ 
acetylated sites and blue points show phosphorylated sites. The circular ubiquitinated sites K50, K401 
and K247 were identified in WT TRIM32 in a previous MS study. The LGMD2H disease mutant, which 
do not undergo self-ubiquitination, displayed no ubiquitination of these residues (Figure is modified 
from Phosphosite plus). 
 
4.1. Establishment of mammalian expression plasmids for EGFP-
TRIM32 K50R, EGFP-TRIM32 K247R and EGFP-TRIM32 K401R  
In order to analyze if TRIM32 self-ubiquitination takes place on any of the residues K50, K247 
or K401, EGFP-TRIM32 expression plasmids with each of the lysine residues mutated to 
arginine was established by site directed mutagenesis. The mutagenesis was performed on the 
mammalian expression vector pDEST-EGFP-TRIM32 and the donor vector pDONR221-
TRIM32. The mutagenesis primers were TRIM32-K50R, TRIM32-K247R and TRIM32-K401 
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R (Table 3). The mutagenesis reaction mixtures were transformed into E. coli and plated onto 
LB+amp plates for the pDEST vectors and LB+kan plates for the pDONR vectors. Plasmids 
from three E. coli colonies from each reaction were purified by plasmid miniprep, before 
analysis by agarose gel electrophoresis and DNA sequencing. 
The DNA sequences were analyzed by Chromas software (technelysium.com.au/wp/chromas) 
and NCBI BLAST (https://blast.ncbi.nlm.nih.gov). Lysine to arginine mutations was obtained 
for all three residues as shown in Figure 19. 
 
Figure 19: Schematic of TRIM32 domain organization and the location of the three lysines K50, K247 
and K401. Below are the sequencing results of the mutated plasmids with the K to R codons marked in 
yellow (Complete sequencing result found in appendix). 
 
4.2. Introduction of the single mutations K50R, K247R or K401R in 
TRIM32 did not abolish self-ubiquitination 
To investigate if the introduction of the K to R mutations at positions 50, 247 or 401 would 
affect self-ubiquitination of TRIM32, the pDEST-EGFP-TRIM32 K50R, pDEST-EGFP-
TRIM32 K247R and pDEST-EGFP-TRIM32 K401R plasmids were transfected into two 
different breast cancer cell lines, MDA-MB-231 and MCF-7 along with the pDEST-EGFP-
TRIM32 wild type expression plasmid. One day post transfection the cells were harvested in 
SDS lysis buffer and cell extracts separated by SDS-PAGE. Expression of EGFP-TRIM32 wild 
type and mutants were detected by Western blotting using an anti-GFP antibody. 
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When TRIM32 is mono-ubiquitinated by self-ubiquitination, it migrates slower in the SDS-
PAGE gel seen as a band just above the band representing un-ubiquitinated TRIM32 (Overa et 
al., 2019) (Figure 20). EGFP-TRIM32 WT and the three mutants were similarly expressed in 
both cell lines and the mono-ubiquitin band could be observed in all samples (Figure 20). This 
shows that mutations of the lysines 50, 247 or 401 in TRIM32 did not abolish self-
ubiquitination. The membrane was reblotted by an anti-PCNA antibody, to show that similar 
amounts of cell extracts were loaded in each well (Figure 20). 
Figure 20: Introductions of K50R, K247R or K401R mutations in TRIM32 did not abolish 
self-ubiquitination. Western blot analysis of EGFP-TRIM32 WT, EGFP-TRIM32 K50R, EGFP-
TRIM32 K247R or EGFP-TRIM32 K401R expressed in MDA-MB-231 and MCF-7 cell lines. The cells 
were transfected with the indicated pDEST-EGFP-TRIM32 plasmids one day before harvesting for 
Western blotting. The EGFP-TRIM32 proteins were detected using an anti-GFP antibody. The upper 
band represents mono-ubiquitinated EGFP-TRIM32, while the lower major band displays un-
ubiquitinated EGFP-TRIM32. Blotting using an anti-PCNA antibody was used as loading control. 
 
4.3. Establishment of EGFP-TRIM32 K247R/K401R, K50R/K247R and 
K50R/K401R expression plasmids  
Since mutations of single lysine residues did not impair TRIM32 self-ubiquitination, our next 
question was if introduction of double K to R mutations would affect its self-ubiquitination 
activity. EGFP-TRIM32 expression plasmids with the lysine K50/K247, K50/K401 and 
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K247/K401 residues mutated to arginine were established by site directed mutagenesis as 
described above. Plasmids from three E. coli colonies from each reaction were purified by 
plasmid miniprep before analysis by DNA sequencing. 
The DNA sequences were analyzed by Chromas software (technelysium.com.au/wp/chromas) 
and NCBI BLAST (https://blast.ncbi.nlm.nih.gov). Lysine to arginine mutations were obtained 
for all residues as shown in Figure 21. 
 
 
Figure 21: Sequencing results from the introduction of the double lysine mutations K50/K247, 
K247/K401 and K50/K401 in pDEST-EGFP-TRIM32. Below are the sequencing results of the mutated 
plasmids with the K to R codons marked in yellow (Complete sequencing result found in appendix). 
 
4.4. Introduction of the K247R/K401R mutations in EGFP-TRIM32 
results in an unstable protein 
To investigate if the introduction of the K to R double mutations K247R/K401R, K50R /K247R 
and K50R/K401R would affect self-ubiquitination of TRIM32, the pDEST-EGFP-TRIM32-
K247R/K401R, pDEST-EGFP-TRIM32-K50R/K247R and pDEST-EGFP-TRIM32-K50R/ 
K401R plasmids were transfected into HeLa cell lines along with the pDEST-EGFP-TRIM32 
wild type expression plasmid. One day post transfection the cells were harvested in SDS lysis 
buffer and cell extracts separated by SDS-PAGE. Expression of EGFP-TRIM32 wild type and 
mutants were detected by Western blotting using an anti-GFP antibody. Figure 22 shows that 
EGFP-TRIM32 WT and the double mutants K50R/K247R and K50R/K401R are similarly 
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expressed in HeLa cell lines and the mono-ubiquitin band can be observed in all samples. 
However, the K247R/K401R mutant displays a weak full-length band, but a strong band with 
higher mobility in the gel. This indicates that mutations of the lysines K247R/K401R results in 
an unstable EGFP-TRIM32 protein. Hence, post translational modifications on lysine 247 and 
lysine 401 seem to be important for the stability of TRIM32. Importantly, the weak bands of 
full-length EGFP-TRIM32 K247R/K401R suggest that this double mutant still can undergo 
self-ubiquitination, suggesting that self-ubiquitination as such is not enough to stabilize the 
protein. 
 
Figure 22: Introduction of the K247R/K401R mutations in EGFP-TRIM32 results in an 
unstable protein. Western blot analysis of EGFP-TRIM32 WT, EGFP-TRIM32-K247R/K401R, 
EGFP-TRIM32-K50R/K247R and EGFP-TRIM32-K50R/K401R expressed in HeLa cells. The cells 
were transfected with the indicated pDEST-EGFP-TRIM32 plasmids one day before harvesting for 
Western blotting. The EGFP-TRIM32 proteins were detected using an anti-GFP antibody. The upper 
band represents mono-ubiquitinated EGFP-TRIM32, while the lower major bands display un-
ubiquitinated EGFP-TRIM32 along with cleaved EGFP-TRIM32. Blotting using an anti-PCNA 
antibody was used as loading control. 
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4.5. Establishment of EGFP-TRIM32 K50/K247R/K401R expression 
plasmid 
As shown above, introduction of the K to R double mutations in TRIM32 did not impair self-
ubiquitination activity. We therefore went further to ask if introduction of the triple K to R 
mutation K50R/K247R/K401R would affect self-ubiquitination. An EGFP-TRIM32 
expression plasmid with the three lysine residues mutated to arginine was established by site 
directed mutagenesis. The mutagenesis was performed on the mammalian expression vector 
pDEST-EGFP-TRIM32 K247R/K401R and the mutagenesis primers were TRIM32-K50R 
forward and reverse (Table 3). The mutagenesis reaction mixture was transformed into E. coli 
and plated onto LB+amp plates. Plasmids from three E. coli colonies were purified by plasmid 
miniprep before analysis by DNA sequencing.  
The DNA sequences were analyzed by Chromas software (technelysium.com.au/wp/chromas) 
and NCBI BLAST (https://blast.ncbi.nlm.nih.gov). Lysine to arginine mutations were verified 
for all three residues K50/K401/K247 as shown in Figure 23.     
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Figure 23: Sequencing results from the introduction of the triple lysine mutations EGFP-TRIM32 
K50R/K401R/K247R. Below are the sequencing results of the mutated plasmid with the K to R codons 
marked in yellow (Complete sequencing result found in appendix). 
 
4.6. Introduction of the triple K50R/K247R/K401R mutation in EGFP-
TRIM32 results in cleavage of the protein 
To investigate if the introduction of the triple K to R mutations K50R /K247R/K401R would 
affect self-ubiquitination of TRIM32, the triple mutation plasmid was transfected into HeLa 
cells along with pDEST-EGFP-TRIM32 WT and the double mutants pDEST-EGFP-TRIM32- 
K247R/K401R,pDEST-EGFP-TRIM32-K50R/K247R, pDEST-EGFP-TRIM32-K50R/K401R 
plasmids. In addition, the pDEST-EGFP-TRIM32 WT plasmid was co-transfected with an 
expression plasmid for the mCherry-tagged de-ubiquitinating enzyme USP2. One day post 
transfection the cells were harvested in SDS lysis buffer and cell extracts separated by SDS-
PAGE. Expression of EGFP-TRIM32 wild type and mutants were detected by Western blotting 
using an anti-GFP antibody. The results presented in Figure 24 A show that K to R mutations 
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of the three lysine residues K50, K247 and K401 in TRIM32 make the protein completely 
unstable. Moreover, Figure 24 A also confirm the previous finding that introduction of the 
double K to R mutation K247R/K401R result in a partial unstable protein. Interestingly, de-
ubiquitination of TRIM32 by USP2 did not affect the stability of TRIM32 (Figure 24 A, last 
lane). This suggests that another post-translational modification than ubiquitination at K247 
and K401 is important for the stability of the protein. 
In order to verify these results further, the above experiment was repeated, but this time the 
TRIM32 proteins were detected by the use of an anti-TRIM32 antibody instead of an anti-GFP 
antibody (Figure 24 B). Importantly, Western blotting using the anti-TRIM32 antibody resulted 
in the same band pattern as the anti-GFP antibody. This strongly support our finding that post-
translational modifications other than ubiquitination on the lysine residues K50, K247 and 
K401 are important for the stability of TRIM32.   
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Figure 24: Introduction of the K50R/K247R/K401R mutations in EGFP-TRIM32 results 
in a completely unstable protein. (A) Western blot analysis of EGFP-TRIM32 WT, EGFP-
TRIM32- K247R/K401R, EGFP-TRIM32-K50R/K247R, EGFP-TRIM32- K50R/K401R and EGFP-
K50R/K401R/K247R expressed in HeLa cells without or with co-expressed mCherry-USP2 where 
indicated. The cells were transfected with the plasmids one day before harvesting for Western blotting. 
The EGFP-TRIM32 proteins were detected using an anti-GFP antibody. The upper band represents 
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mono-ubiquitinated EGFP-TRIM32, while the lower major band displays un-ubiquitinated EGFP-
TRIM32 along with cleaved EGFP-TRIM32. Blotting using an anti-PCNA antibody was used as loading 
control. (B) Western blot analysis of similar experiment as described in 24 A, but the antibody used was 
an anti-TRIM32 antibody instead of the anti-GFP antibody. 
 
4.7. A PEST sequence is located adjacent to Lysine K247 in TRIM32 
The analysis so far has been performed in HeLa or breast cancer cell lines, which express 
endogenous TRIM32. TRIM32 is a protein that oligomerize, and this oligomerization leads to 
self-ubiquitination. To investigate if the self-ubiquitination detected in the cell extracts from 
cells transiently expressing K to R TRIM32 mutants was due to oligomerization with wild-type 
endogenous TRIM32, the double and triple K to R mutants of TRIM32 were transfected into a 
HEK293 FlpIn TRIM32 KO cell line (Overa et al., 2019). Western blot analysis displayed 
similar results as described above (Figure 25 A). The double mutations K50R/K247R, 
K50R/K401R and K247R/K401R did undergo self-ubiquitination. Moreover, introduction of 
the double K247R/K401R mutations and the triple K50R/K247R/K401R mutation made 
TRIM32 unstable, while de-ubiquitination by USP2 did not. Altogether, these results confirm 
that single and double K to R mutations of K50, K247 and K401 in TRIM32 do not abolish 
self-ubiquitination.  
The results so far indicate that post-translational modifications of K247 and K401, and to a 
lesser extent also K50 are important for the stability of TRIM32. This prompted us to 
investigate by bioinformatics if TRIM32 contains a PEST sequence. Interestingly, the PEST 
prediction software EMBOSS: epestfind identified a putative PEST sequence (PEST score 7.4) 
at position 248–270, adjacent to the K247 residue (Figure 25 B). The PEST sequence is 100% 
conserved in mammalian TRIM32 proteins. These results suggest that post-translational 
modification of lysine K247 protects TRIM32 from degradation directed by the PEST 
sequence. However, when the lysine 247 residue together with lysine residue K401 is mutated 
to arginine that cannot be modified by post-translational modifications, TRIM32 is exposed to 
cleavage. 
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Figure 25: A PEST sequence is located adjacent to K247 in TRIM32. (A) Western blot 
analysis of EGFP-TRIM32 WT, EGFP-TRIM32- K247R/K401R, EGFP-TRIM32-K50R/K247R, 
EGFP-TRIM32-K50R/K401R, EGFP-K50R/K401R /K247R and EGFP-TRIM32 WT co-expressed 
with mCherry-USP2 in HEK293 FlpIn TRIM32 KO cells. The cells were transfected with the indicated 
pDEST-EGFP-TRIM32 plasmids one day before harvesting for Western blotting. The EGFP-TRIM32 
proteins were detected using an anti-TRIM32 antibody. The upper band represents mono-ubiquitinated 
EGFP-TRIM32, while the lower major band displays un-ubiquitinated EGFP-TRIM32 along with 
cleaved EGFP-TRIM32. Blotting using an anti-PCNA antibody was used as loading control. (B) 
Schematic of the domain structure of TRIM32 with the conserved putative PEST sequence. TRIM32 
domain organization along with the localization of the disease point mutations P130S (BBS11) at the 
B2 box and D487N (LGMDH2) at NHL repeats domain are shown. The three lysine residues mutate in 
this work are indicated in red above the schematic. R, Ring finger; B2, Bbox2; CC, Coiled coil (Obtained 
and modified from (Overa et al., 2019). 
 
4.8. Inhibition of the lysosome or the proteasome does not inhibit 
cleavage of TRIM32 K50R/K247R/K401R 
To investigate if the cleavage of TRIM32 was performed by proteases in the lysosome or 
proteases in the proteasome, cells were next treated with the proteasomal inhibitor MG132 or 
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the lysosomal inhibitor Bafilomycin A1 (BafA1). The pDEST-EGFP-TRIM32 WT and the 
pDEST-EGFP-K50R/K247R/K401R plasmids were transfected into HEK293 FlpIn TRIM32 
KO cells. The cells were treated with MG132 (20 M) or BafA1 (0,2 M) for three hours one 
day post transfection (Figure 26 A) or with MG132 (5 M) or BafA1 (0,1 M) at the time of 
transfection for 24 hrs (Figure 26 B). The cells were grown in Full Medium or starvation 
medium (HBSS) for three hrs before harvesting. The cells were harvested in SDS lysis buffer 
and cell extracts separated by SDS-PAGE. Expression of EGFP-TRIM32 wild type and triple 
mutants were detected by Western blotting using an anti-GFP antibody. Neither 3 hours nor 24 
hours treatments with the MG132 inhibitor or BafA1 inhibited cleavage of the triple K to R, 
K50R/K247R/K401R, mutant of TRIM32. This may suggest that TRIM32 is cleaved by a 
protease not associated with the proteasome or with the lysosome, or by both. 
 
Figure 26: Inhibition of the lysosome or the proteasome does not inhibit cleavage of 
EGFP-TRIM32 K50R/K247R/K401R. (A) Western blot analysis of EGFP-TRIM32 WT and 
EGFP-K50R/K401R /K247R expressed in HEK293 FlpIn TRIM32 KO cells lines. The cells were 
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transfected with the indicated pDEST-EGFP-TRIM32 plasmids one day before harvesting for Western 
blotting. The EGFP-TRIM32 proteins were detected using an anti-GFP antibody. Blotting using an anti-
PCNA antibody was used as loading control. Inhibitor treatment of MG132 (20 µM) or BafA1 (0,2 µM) 
for three hours and one day post transfection (FM: Full Media, SM: Starvation Media, Baf: Bafilomycin 
A1, MG: MG132). (B) Western blot analysis of EGFP-TRIM32 WT and EGFP-TRIM32-K49R/K401R 
/K247R expressed in HEK293 FlpIn TRIM32 KO cells lines. The cells were transfected with the 
indicated pDEST-EGFP-TRIM32 plasmids one day before harvesting for Western blotting. The EGFP-
TRIM32 proteins were detected using an anti-GFP antibody. Blotting using an anti-PCNA antibody was 
used as loading control. The inhibitors MG132 (5 µM) and BafA1 (0,1 µM) were added at the time of 
transfection and stayed for 24 hrs. Starvation (HBSS) was performed for 3 hrs before harvesting. (FM: 
Full Media, SM: Starvation Media, Baf: Bafilomycin A1, MG: MG132).  
 
4.9. EGFP-TRIM32 WT and mutants colocalize with Golgi marker 
GM130 and autophagy receptor p62/SQSTM1  
Previous studies have shown that TRIM32 localizes to cytoplasmic dots, and that it co-localizes 
with the autophagy receptor p62/SQSTM1 in some of these dots. To investigate if introduction 
of the double K to R mutations and the triple K to R mutation in TRIM32 would affect the 
localization of TRIM32, fluorescent confocal imaging was applied. 
The pDEST-EGFP-TRIM32-K247R/K401R, pDEST-EGFP-TRIM32-K50R/K247R, pDEST-
EGFP-TRIM32- K50R/K401R and pDEST-EGFP-K50R/K401R /K247R plasmids were 
transfected into HEK293 FlpIn TRIM32 KO cells along with the pDEST-EGFP-TRIM32 wild 
type and pDEST-EGFP expression plasmids. One day post transfection cell fixation and 
immunostaining were performed with antibodies against the Golgi protein GM130 and the 
autophagy receptor p62/SQSTM1. The cell nucleus was visualized by DAPI staining. 
Figure 27 A shows the distribution of GFP, and the normal staining of Golgi GM130 and 
p62/SQSTM1. Aggregation is not a general trait of EGFP, and most cells displayed a diffused 
EGFP localized all over the nucleus and cytoplasm. GM130 stained a perinuclear structure 
indicative of the Golgi apparatus, while p62/SQSTM1 appeared as dots dispersed throughout 
the cytoplasm. 
EGFP-TRIM32 displayed a localization pattern as described by others. It forms several 
cytoplasmic dots, and when over-expressed it has a tendency to form large cytoplasmic 
aggregates. Both p62/SQSTM1 and GM130 colocalized with TRIM32 in some small dots, and 
in the large aggregates (Figure 27 B).  
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The K to R triple mutant EGFP-TRIM32 K50R/K247R/K401R formed larger and more 
cytoplasmic aggregates than TRIM32 WT (Figure 27 C). Some of the aggregates displayed 
colocalization with GM130 and p62/SQSTM1. However, the colocalization seemed to be much 
less prominent, indicating that the cleaved form of TRIM32 has less ability to aggregate the 
Golgi protein GM130 and autophagy receptor p62/SQSTM1. The K to R double mutant EGFP-
TRIM32 K50R/K247R displayed a localization and colocalization pattern very similar to 
EGFP-TRIM32 WT (Figure 27 D). The K to R double mutants EGFP-TRIM32 K50R/K401R 
(Figure 27 E) and EGFP-TRIM32 K247R/K401R (Figure 27 F) showed a very similar 
localization pattern. In some cells they displayed a diffuse staining throughout the cytoplasm 
in addition to some cytoplasmic aggregates, while in other cells they accumulated to large 
aggregates. Both the small and the large aggregates showed colocalization of GM130 and 
p62/SQSTM1. 
Altogether, these results may indicate that full-length TRIM32 has a strong tendency to 
aggregate the Golgi protein GM130 and the autophagy receptor p62/SQSTM1, while the 
cleaved TRIM32 protein has a strong tendency to formed aggregates, but less ability to co-
aggregate GM130 and p62/SQSTM1.  
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Figure 27: EGFP-TRIM32 WT and mutants colocalize with Golgi marker GM130 and 
autophagy receptor p62/SQSTM1. HEK293 FlpIn EGFP-TRIM32 KO cells transfected with 
EGFP (A), EGFP-TRIM32 WT (B), EGFP-TRIM32 K50R/K247R/K401R (C), EGFP-TRIM32 
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K50R/K247R (D), EGFP-TRIM32 K50R/ K401R (E), EGFP-TRIM32 K247R/K401R (F) expression 
plasmids. One day post transfection the cells were fixed and stained with antibodies against GM130 
(Golgi: red) and p62 (white). The images were obtained by using a ZEISS780 confocal laser scanning 
microscope and the colocalization monitored by using the ZEN software. Scale bars: 10 µm. 
 
4.9. Establishment of CRISPR/Cas9 plasmids directed against T1 
and T2 target sites in mouse TRIM32 and T1 target site in rat TRIM32 
Since mutations in TRIM32 are implicated in the development of muscle dystrophy, myoblast 
cell lines that have the ability to differentiate into muscle cells would be a promising model 
system for studying the functionality of TRIM32. Here the mouse myoblast cell line C2C12 
and the rat myoblast cell line H9c2 were chosen for an attempt to make a myoblast TRIM32 
KO cell line. For this purpose, the bioinformatics tool CHOPCHOP (https://chopchop 
.cbu.uib.no/) was applied to identify promising Cas9 target sites in the mouse and rat TRIM32 
genes. Two gRNA sequences were selected for each gene (mouse T1 and T2, and rat T1 and 
T2). Forward and reverse oligoes for each target site were phosphorylated and annealed, before 
they were ligated into the CRISPR/Cas9 plasmid pX458 (Ran, Hsu, Wright, et al., 2013), which 
also expresses the EGFP protein. The ligation mix was transformed into E. coli and plated on 
LB+amp plates. Three colonies from each plate were purified by plasmid miniprep and 
successful cloning verified by restriction enzyme digestion and DNA sequencing. Analysis of 
the DNA sequences showed that the gRNAs directed against mouse T1 and T2 targets sites, 
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Figure 28: gRNA sequences against mouse TRIM32 and rat TRIM32 were successfully cloned into 
the pX458 CRISPR/Cas9 vector. DNA Sequencing results of the pX458 plasmids with inserted gRNAs 
directed against mouse T1 and T2 targets sites and the gRNA directed against the rat T1 target site are 
marked in yellow (Complete sequencing result found in appendix). 
 
4.10. Establishment of myoblast C2C12 TRIM32 KO cell lines 
To investigate if these three CRISPR/Cas9 plasmids had the ability to generate TRIM32 KO 
cell lines, the plasmids were transfected into the mouse myoblast C2C12 cell line, and the rat 
H9c2 cell line, respectively. Successfully transfected cells were selected based on the 
expression of EGFP and sorted as single cells into a well in a 96 well dish. The C2C12 cells 
grew well, and around 20 cell colonies for each of the target sites were picked and amplified 
further for analysis by Western blotting. The rat H9c2 cell cultures did not grow well, and no 
colonies were picked for further analysis. When the selected colonies were expanded up to a 
12-well dish, the cells were harvested in SDS lysis buffer and cell extracts separated by SDS-
PAGE. The presence or absence of TRIM32 in the cell extracts were analyzed by using an anti-
TRIM32 antibody. Extracts from HEK293 cells were used as positive controls.  
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Figure 29 shows that the expression level of TRIM32 varies significantly between the different 
clones. However, the two clones T1-16 and T2-1 seem to completely lack the expression of 
TRIM32, and hence are potential candidates for establishment of myoblast TRIM32 KO cell 
lines. Freezer stocks were made of these two potential clones for further analysis by the MCRG. 
 
 
Figure 29: Establishment of TRIM32 KO clones in the myoblast C2C12 cell line. Western 
blot of cell extracts from the various expanded CRISPR/Cas9 clones of the C2C12 cell line. Extracts 
were blotted against an anti-TRIM32 antibody, and extracts from a HEK293 cell line were run in parallel 
as a positive control. Reblotting using the PCNA antibody shows the amount of cell extracts loaded in 




LGMD2H is a muscle dystrophy disease, which is caused by mutations in the ubiquitin 
ligase TRIM32, whose function in the muscles is not completely understood (Di Rienzo et al., 
2019). However, it is shown that activation of TRIM32 is regulated by oligomerization and 
self-ubiquitination. The LGMD2H mutant form of TRIM32 is unable to undergo self-
ubiquitination, and it is shown that it is unable to ubiquitinate the autophagy receptor 
p62/SQSTM1 and to be an autophagic substrate itself (Overa et al., 2019). LGMD2H (MIM 
254110) is a gentle mode of autosomal recessive muscular dystrophy with a changeable clinical 
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presentation. The beginning is commonly within the 2d or 3d decade of life, and advancement 
is slow. The greater number of patients have continued ambulatory into the 6th decade of life. 
There is no indication of cardiac or facial symptoms (Frosk et al., 2002).  
TRIM32 due to its E3 ubiquitin ligase activity has been demonstrated to direct degradation of 
various targets, so the absence or abnormal function of TRIM32, which is caused by recessive 
mutations would lead to the loss of ubiquitination as well as aggregation of the TRIM32 
substrates (Servián-Morilla et al., 2019). This ubiquitously expressed nature of TRIM32 
suggests that it plays an important role in other tissues, such as cardiac and smooth muscle but 
also in epithelia and brain tissues, where its expression is at high level (Cohen et al., 2012). The 
ubiquitin proteasome system (UPS) has been shown to play a significant role in mediating 
muscle wasting (Bilodeau, Coyne, and Wing, 2016). The purpose of this work was to identify, 
which lysine residues in TRIM32 are targets for its self-ubiquitination activity. Three lysine 
residues that were previously identified as potential targets by mass spectrophotometry analysis 
were mutated to arginine, which are unable to be modified by ubiquitin. Unfortunately, 
mutation of all three lysine residues did not abolish self-ubiquitination activity. This do not rule 
out that these lysines are targets for self-ubiquitination. However, it shows that also other lysine 
residues in TRIM32 are targets for self-ubiquitination. Identification of these residues needs 
further mutational analysis followed by Western Blotting in further study.  
 
5.1. PEST sequences role in protein stability  
Surprisingly, introduction of the K247R/K401R mutations in TRIM32 resulted in an unstable 
protein, giving a cleavage product of TRIM32 of around 30 kDa in the SDS gel. Bioinformatic 
analysis predicted a conserved PEST sequences adjacent to the K247 residue. The PEST 
hypothesis was first proposed in 1986 by Rechsteiner and his colleagues, which is based upon 
the presence of polypeptide sequence regions enriched in proline (P), glutamic acid (E), aspartic 
acid (D), serine (S), and threonine (T) confined by two positively charged amino acids, lysine 
(K), arginine (R) or histidine (H) in many short-lived proteins. These regions are hydrophilic 
and at least 12 amino acids long, while being not present in more stable proteins with half-lives 
of more than 20 h. Hence, PEST sequences are signals for rapid degradation of target proteins 
(Spencer, Theodosiou, and Noonan, 2004; Pakdel, Le Goff, and Katzenellenbogen, 1993; Qile 
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et al., 2019; Reverte, Ahearn, and Hake, 2001). Certainly, in many short living proteins, the 
mutation of the PEST domain sequences results in the stabilization of the proteins and might 
affect nuclear localization of some proteins. Moreover, in many proteins PEST sequences 
appear to function as anchor sites of E3 ubiquitin ligases, which are required for ubiquitin 
dependent protein degradation (Qile et al., 2019; Park, Jeong, and Kim, 2014). Generally, the 
PEST regions are flanked by clusters that contain various positively charged amino acids. Based 
on these observations, there are developed algorithms that identify putative PEST regions in 
protein sequences (Rogers, Wells, and Rechsteiner, 1986; Chen and Clarke, 2002). 
A lot of evidence supports the idea that PEST sequences target proteins for degradation by the 
26S proteasome (Rechsteiner and Rogers, 1996; Chen and Clarke, 2002). A strong connection 
has been established between nuclear protein stability and the existence of PEST regions 
(Chevaillier, 1993). Ramakrishna et al., (2011) results suggest that a PEST motif found in the 
NANOG protein is necessary for an effective NANOG ubiquitination and the deletion of this 
PEST motif result in increased stability of NANOG protein by abolishing its ubiquitination 
(Ramakrishna et al., 2011). 
Here we find that K247 in TRIM32 is located at the start of a PEST sequence (Figure 25 B). 
Introduction of lysine to arginine mutations of K247 and K401 resulted in an unstable protein. 
This suggests that post translational modifications on lysine 247 and lysine 401 are important 
for the stability of TRIM32. Importantly, presence of the self-ubiquitination band in the 
Western blot of EGFP-TRIM32 K247R/K401R suggests that this double mutant still can 
undergo self-ubiquitination. Furthermore, de-ubiquitination of TRIM32 by USP2 did not affect 
the stability of TRIM32 (Figure 24A, last lane). Hence, ubiquitination of these residues seems 
not to be enough to stabilize the protein (Figure 22), suggesting that other post-translational 
modifications such as acetylation, methylation or sumoylation might important for protecting 
TRIM32 from degradation mediated by the PEST sequence. This will be an interesting topic 
for further studies. 
The identification of a PEST sequence in TRIM32 raised the question whether this sequence 
directs TRIM32 cleavage by the proteasome or in the lysosome. In order to analyze this, 
proteasomal inhibitor MG132 and lysosomal inhibitor BafA1 were applied on cells expressing 
the triple K to R mutant form of TRIM32. Bafilomycin A1 is a member of the family of 
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macrolide antibiotic, which was among the first of this class segregated from Streptomyces 
gresius. It is an effective inhibitor of the Vacuolar H+ ATPase, which controls pH activity in 
the lysosome (V-ATPase). By using this mechanism Bafilomycin A1 is capable of preventing 
autophagic flux by inhibiting the acidification of endosomes as well lysosomes bodies 
(Redmann et al., 2017).  
The cells were treated with MG132 or BafA1 for three hours one day post transfection (Figure 
26 A) or with MG132 or BafA1 at the time of transfection and for 24 hrs (Figure 26 B). The 
cells were incubated in Full Medium or starvation medium (HBSS, 3 hrs) before harvesting. 
However, neither 3 hours nor 24 hours treatments with the MG132 inhibitor or BafA1 inhibited 
cleavage of the TRIM32 K50R/K247R/K401R mutant. This suggests that TRIM32 is cleaved 
by a protease not associated with the proteasome or with the lysosome or can be cleaved by 
both. Hence, treatment with both MG132 and BafA1 in the same cell culture should be 
performed in future studies. According to Overa et al., (2019) endogenous wild type TRIM32 
is degraded by both lysosomal pathways and the proteasome in HEK293 cells. The treatment 
of both the lysosomal and the proteasomal inhibitor increased the amount of TRIM32 to a 
similar extent under starvation conditions, whereas the proteasomal pathway appears to be most 
important under normal cellular conditions (Overa et al., 2019).  
 
5.2. Mouse myoblast (C2C12) TRIM32-KO cell lines as model system 
to study the function of TRIM32 in muscle cells  
The mouse myoblast (C2C12) cells are used as a model system to study the various kinds of 
muscular dystrophies such as Duchenne muscular dystrophy (DMD), Emery–Dreifuss 
muscular dystrophy (EDMD) and limb–girdle muscular dystrophy (LGMD) in vitro. The 
mouse myoblast (C2C12) cells myotube or fibrin gel system has been grown to show that the 
cells in fibrin gels draw out better level of contractile activity compared than mouse myoblast 
(C2C12) cultures on conventional two-dimensional surfaces. The mouse myoblast (C2C12) 
when deprived of serum go through cell cycle capture and start to combine and form a 
multinucleated myotubes. The myotubes serve as the building blocks for skeletal muscle, so in 
this manner understanding of the differentiation process of mouse skeletal myoblasts (C2C12) 
in vitro has the possibility to resolve the mechanisms of the myogenic differentiation process 
in vivo as well (Bajaj et al., 2011). The study conducted by Bajaj et al., (2011) showed that the 
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geometrical hints deliberated by the protein micropatterns possibly manage to various tractional 
stresses and cytoskeletal restructuring of C2C12 myoblast cells, which further produced various 
degrees of differentiation on the distinct geometries. They found that geometrical hints 
influence the differentiation process of C2C12 myoblasts cells, and that the differentiation of 
C2C12 myoblasts cells are found on three main geometries; a linear, a circular and a hybrid 
pattern. The hybrid 30° pattern appeared as the best geometry to expand the differentiation of 
C2C12 myotubes (Bajaj et al., 2011). 
It is demonstrated that TRIM32 is involved in the managing of differentiation and self-
regeneration of neural progenitor cells during mouse embryonic brain development. 
Furthermore, the Drosophila orthologs of TRIM32, Brat and the Brat-like protein called Mei-
p26 control stem cell proliferation, which is found in the Drosophila nervous system and 
ovaries, respectively. So, in this manner, the control of stem cell proliferation might be a typical 
function of TRIM-NHL proteins and deregulation of muscle stem cell activity upon failure of 
TRIM32 could provide to the development of LGMD2H (Nicklas et al., 2012). According to 
Nicklas et al., (2012) TRIM32 is enough to induce muscular differentiation of mouse myoblast 
(C2C12) cells, while upon knock-down of TRIM32 the differentiation of C2C12 cells is 
restricted. Similarly, it is demonstrated that TRIM32 is implicated in muscle differentiation and 
that differentiation possibly depends upon the ubiquitination and degradation of c-Myc 
(Oncogene). Overall, it is proved that TRIM32 knock-out mice produces a myopathy that 
conferred by LGMD2H patients and that muscle transformation in these mice was highly 
delayed and damaged. Based on these experimental findings, it was proposed that loss of 
TRIM32 function in the muscle stem cells will diminish their functionality. This dysfunction 
of the muscle stem cells could lead to the etiology of LGMD2H (Nicklas et al., 2012).   
Mokhonova et al., (2015) created a genetically modified mice that were deficient of TRIM32 
(T32KO) and noticed that they exhibited both the myopathic and neurogenic phenotypes. The 
muscles of these mice showed a mild muscular dystrophy and presented dystrophic 
characteristics, which are similar to those found in patients with the muscular disorders 
LGMD2H. Similarly, the T32KO mice showed a decline in the concentration of neurofilament 
proteins, which are found in the brain and a decreased motor axon diameter. these neurogenic 
features are also visible in LGMD2H patients (Mokhonova et al., 2015). TRIM32 knockout 
mouse was also created by Kudryashova, Kramerova, and Spencer, (2012), which proved to be 
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a good model for studying the pathogenic mechanisms of LGMD2H. In this TRIM32 KO 
mouse model, the absence of TRIM32 resulted in a similar kind of myopathic phenotype as 
demonstrated in LGMD2H along with similar type of muscle morphology and muscle weakness 
on grip strength (Kudryashova, Kramerova, and Spencer, 2012; Kudryashova et al., 2011).  
In this work, mouse myoblast (C2C12) TRIM32-KO cell lines were established by 
CRISPR/Cas9. The knockout of TRIM32 expression in the cell lines was verified by Western 
blotting. The expression level of TRIM32 varied between the different clones. However, the 
two clones T1-16 and T2-1 (Figure 29) seem to completely lack the expression of TRIM32, 
and hence are potential candidates for further studies. First, verification of the TRIM32 KO has 
to be performed by sequencing the genomic region in TRIM32 targeted by the gRNA 
sequences. Thereafter, stable TRIM32 KO cells with expression of tagged TRIM32 wild-type, 
LGMD2H disease mutant or BBS11 disease mutant forms can be established by virus 
transduction. These cell lines, together with the TRIM32 KO cell lines and the normal C2C12 
cell line, will be applied in various studies to understand the pathogenic role of the disease 
mutations for the development of the related disease. 
 
Conclusion 
In this work self-ubiquitination of the K50, K247 and K401 sites in TRIM32 was analyzed by 
site-directed mutagenesis. Introduction of single or double K to R mutations did not seem to 
abolish self-ubiquitination. However, the introduction of the double K247R/K401R mutations 
in EGFP-TRIM32 results in an unstable protein and the introduction of the triple 
K50R/K247R/K401R mutation in EGFP-TRIM32 results in cleavage of the protein. The 
inhibition of the lysosome or the proteasome did not inhibit cleavage of TRIM32 
K50R/K247R/K401R. This suggest that post-translational modifications of TRIM32 at the 
K247 and K401 residues protects TRIM32 from proteolytic cleavage, and this protection is 
further enhanced by modifications on K50. Localization studies in HEK293 FlpIn TRIM32 KO 
cells showed that EGFP-TRIM32 WT and the K to R double and triple mutants had a tendency 
to aggregate in the cytoplasm, clustering with the Golgi protein GM130 and the autophagy 
receptor p62/SQSTM1. Finally, two myoblast C2C12 TRIM32 KO cell lines were successfully 
established. 
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6. Future work 
For the future work, it would be interesting to investigate the effect of expressing the TRIM32 
disease mutations in the C2C12 myoblast cell line compared to expression of wild type 
TRIM32. Especially, it will be interesting to analyze the autophagy process in these cells, and 
to determine whether the pathology of the LGMD2H mutation is due to dysfunctional 
degradation of specific muscle proteins. Furthermore, since the C2C12 cells can be induced to 
differentiate into muscle fibers, the TRIM32 KO cell line can be used to study whether TRIM32 
affects protein degradation during differentiation.  
The lysine residues in TRIM32 involved in self-ubiquitination were not mapped in this work. 
Thus, it would be interesting to investigate more ubiquitinated sites that are found in EGFP-
TRIM32. 
In this work we identified K247 and K401 as important residues for protection of TRIM32 
against proteolytic cleavage directed by a predicted PEST sequence. Our data suggest that post-
translational modifications other that ubiquitination is important for this protection. It will be 
interesting in further studies to identify, which post-translational modification (acetylation, 
methylation, sumoylation) that takes place on these lysine residues, and also to identify under 
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Appendix 
List of single, double and triple mutated cloned sequences 
Clone 1: pDEST-EGFP-TRIM32-K50R 
Query  89    ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  148 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
 
Query  149   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  208 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  209   CATACCATCTGCCGCCAGTGCCTGGAGCGCCTATTGGCCAGTAGCATCAATGGTGTCCGC  268 
             |||||||||||||||||||||||||||   |||||||||||||||||||||||||||||| 
Sbjct  324   CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  269   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  328 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  329   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  388 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  389   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  448 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  449   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCCACTGTACACCTCCCCTGTTCAA  508 
             ||||||||||||||||||||||||||||||||||||| ||||||||| |||| || |||| 
Sbjct  564   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCC-ACTGTACAC-TCCC-TG-TCAA  619 
 
Clone 2: pDEST- EGFP-TRIM32-K247R 
Query  87    ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  146 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
 
Query  147   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  206 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  207   CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  266 
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             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  324   CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  267   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  326 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  327   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  386 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  387   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  446 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  447   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  506 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  623 
 
Query  507   GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  566 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624   GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  683 
 
Query  567   GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  626 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  684   GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  743 
 
Query  627   TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  686 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  744   TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  803 
 
Query  687   CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  746 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  804   CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  863 
 
Query  747   GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  806 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  864   GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  923 
 
Query  807   TACTTCCTGGCCAAGATCCGCCAGGCAGATGTAGCACTACTGGAGGAGACAGCTGATGAG  866 
             ||||||||||||||||||   ||||||||||||||||||||||||||||||||||||||| 
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Clone 3: pDONR- EGFP-TRIM32-K401 (Transfer into pDest by GATEWAY LR 
reaction) 
 
Query  665   TGGTTTGCTCAGCTGGCTCCTGTGACAGGCCACGCAGTGGCCATCCAAGGTATATACCTT  724 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1903  TGGTTTGCTCAGCTGGCTCCTGTGACAGGCCACGCAGTGGCCATCCAAGGTATATACCTT  1844 
 
Query  725   GAGGGAGTTATCATAGCTGTCAGTCACACCAATCAGCCCCTGGCAGTTCATTGCCACTGA  784 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1843  GAGGGAGTTATCATAGCTGTCAGTCACACCAATCAGCCCCTGGCAGTTCATTGCCACTGA  1784 
 
Query  785   GAGAGGAGTGAGGTTGGGTAGATCTGCCCCAAGGAAGCTTAGCACAAAGCTATCAATGCC  844 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1783  GAGAGGAGTGAGGTTGGGTAGATCTGCCCCAAGGAAGCTTAGCACAAAGCTATCAATGCC  1724 
 
Query  845   ACTGGGGCTGCGGCGGATTTCCTTCAAAAAGCCGCGGCGGGTAAAGACTTGTATACGATA  904 
             |||||||||||||||||||||||||||||||||   |||||||||||||||||||||||| 
Sbjct  1723  ACTGGGGCTGCGGCGGATTTCCTTCAAAAAGCCTTTGCGGGTAAAGACTTGTATACGATA  1664 
 
Query  905   GTTACCACGGTCAGCGACTAGTACTTCACCTTGACTGGTCACGTAGAGACTGACTGGAAG  964 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1663  GTTACCACGGTCAGCGACTAGTACTTCACCTTGACTGGTCACGTAGAGACTGACTGGAAG  1604 
 
Query  965   ATTGAACATTCCTGGGAGTGCTGCCTTTGGCCCCCATCTTCTTTGAGAAAGAGGCACTGC  1024 
             ||||||||||||||| ||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  1603  ATTGAACATTCCTGG-AGTGCTGCCTTTGGCCCCCATCTTCTT-GAGAAAGAGGCACTGC  1546 
 
Clone 4: pDEST- EGFP-TRIM32-K247/K401R  
 
Query  69   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  128 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204  ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
 
Query  129  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  188 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  189  CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  248 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  324  CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  249  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  308 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  384  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  309  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  368 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  369  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  428 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  429  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  488 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  623 
 
Query  489  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  548 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  683 
 
Query  549  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  608 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  684  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  743 
 
Query  609  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  668 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  744  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  803 
 
Query  669  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  728 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  804  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  863 
 
Query  729  GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCA-GCTGTGTCTCGCTGTGAC  787 
            ||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||| 
Sbjct  864  GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  923 
 
Query  788  TACTTCCTGGCCAAGATCCGCCAGGCAGATGTAGCACTTACT  829 
            ||||||||||||||||||   ||||||||||||||||| ||| 
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Clone 5: pDONR -TRIM32-K50R/K247 (Transfer into pDest by GATEWAY LR 
reaction) 
Query  95    ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  154 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
 
Query  155   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  214 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264   CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  215   CATACCATCTGCCGCCAGTGCCTGGAGCGCCTATTGGCCAGTAGCATCAATGGTGTCCGC  274 
             |||||||||||||||||||||||||||   |||||||||||||||||||||||||||||| 
Sbjct  324   CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  275   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  334 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384   TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  335   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  394 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444   ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  395   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  454 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504   CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  455   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  514 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564   GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  623 
 
Query  515   GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  574 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624   GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  683 
 
Query  575   GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  634 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  684   GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  743 
 
Query  635   TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGMCCAGGATGAGCTGGCT  694 
             ||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  744   TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  803 
 
Query  695   CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAMGTTGAGAAGTCCAATAGTCAAGTG  754 
             ||||||||||||||||||||||||||||||||||| |||||||||||||||||||||||| 
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Sbjct  804   CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  863 
 
Query  755   GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  814 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  864   GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  923 
 
Query  815   TACTTCCTGGCCAAGATCCGCCAGGCAGATGTAGCACTACTGGAGGAGACAGCTGATGAG  874 
             ||||||||||||||||||   ||||||||||||||||||||||||||||||||||||||| 
Sbjct  924   TACTTCCTGGCCAAGATCAAGCAGGCAGATGTAGCACTACTGGAGGAGACAGCTGATGAG  983 
 
Query  875   GAGGAGCCAGAGCTCACTGCCAGCTTGCCTCGGGAGCTCACCCTGCAAGATGTGGAGCTC  934 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  984   GAGGAGCCAGAGCTCACTGCCAGCTTGCCTCGGGAGCTCACCCTGCAAGATGTGGAGCTC  1043 
 
Query  935   CTTAAGGTAGGTCATGTTGG-CCCCTCCAAATTGGAC  970 
             |||||||||||||||||||| |||||||||||||||| 
Sbjct  1044  CTTAAGGTAGGTCATGTTGGCCCCCTCCAAATTGGAC  1080 
 
 
Clone 6: pDONR -TRIM32-K50/K401R (Transfer into pDest by GATEWAY LR 
reaction)  
 
Query  95   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  154 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204  ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
 
Query  155  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  214 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  215  CATACCATCTGCCGCCAGTGCCTGGAGCGCCTATTGGCCAGTAGCATCAATGGTGTCCGC  274 
            |||||||||||||||||||||||||||   |||||||||||||||||||||||||||||| 
Sbjct  324  CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  275  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  334 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  335  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  394 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  395  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  454 
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            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  455  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  514 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  623 
 
Query  515  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  574 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  683 
 
Query  575  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCMAGG  634 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  684  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  743 
 
Query  635  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  694 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  744  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  803 
 
Query  695  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAAGMTGAGAAGTCCAATAGTCAAGT  754 
            |||||||||||||||||||||||||||||||||| ||| ||||||||||||||||||||| 
Sbjct  804  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTG-AAGTTGAGAAGTCCAATAGTCAAGT  862 
 
Query  755  GGTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCA-GCTGTGTCTCGCTGTGA  813 
            |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  863  GGTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGA  922 
 
Query  814  CTACTTCCTGGCCAAGATCAAGCAGGCAGATGTAGCACTACTGGAGGAGACAGCTGATGA  873 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  923  CTACTTCCTGGCCAAGATCAAGCAGGCAGATGTAGCACTACTGGAGGAGACAGCTGATGA  982 
 
Query  874  GGA  876 
            ||| 
Sbjct  983  GGA  985 
 
Clone 7: pDEST- EGFP-TRIM32- K50R/K401R/K247R  
 
Query  88   ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATAC  147 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| | 
Sbjct  204  ATGGCTGCAGCAGCAGCTTCTCACCTGAACCTGGATGCCCTCCGGGAAGTGCTAGAATGC  263 
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Query  148  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  207 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264  CCCATCTGCATGGAGTCCTTCACAGAAGAGCAGCTGCGTCCCAAGCTTCTGCACTGTGGC  323 
 
Query  208  CATACCATCTGCCGCCAGTGCCTGGAGCGCCTATTGGCCAGTAGCATCAATGGTGTCCGC  267 
            |||||||||||||||||||||||||||   |||||||||||||||||||||||||||||| 
Sbjct  324  CATACCATCTGCCGCCAGTGCCTGGAGAAGCTATTGGCCAGTAGCATCAATGGTGTCCGC  383 
 
Query  268  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  327 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384  TGTCCCTTTTGCAGCAAGATTACCCGCATAACCAGCTTGACCCAGCTGACAGACAATCTG  443 
 
Query  328  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  387 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444  ACAGTGCTAAAGATCATTGATACAGCTGGGCTCAGCGAGGCTGTGGGGCTGCTCATGTGT  503 
 
Query  388  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  447 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504  CGGTCCTGTGGGCGGCGTCTGCCCCGGCAATTCTGCCGGAGCTGTGGTTTGGTGTTATGT  563 
 
Query  448  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  507 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564  GAGCCCTGCCGGGAGGCAGACCATCAGCCTCCTGGCCACTGTACACTCCCTGTCAAAGAA  623 
 
Query  508  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  567 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624  GCAGCTGAGGAGCGGCGTCGGGACTTTGGAGAGAAGTTAACTCGTCTGCGGGAACTTATG  683 
 
Query  568  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  627 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  684  GGGGAGCTGCAGCGGCGGAAGGCAGCCTTGGAAGGTGTCTCCAAGGACCTTCAGGCAAGG  743 
 
Query  628  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  687 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  744  TATAAAGCAGTTCTCCAGGAGTATGGGCATGAGGAGCGCAGGGTCCAGGATGAGCTGGCT  803 
 
Query  688  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  747 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  804  CGCTCTCGGAAGTTCTTCACAGGCTCTTTGGCTGAAGTTGAGAAGTCCAATAGTCAAGTG  863 
 
Query  748  GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  807 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  864  GTAGAGGAGCAGAGTTACCTGCTTAACATTGCAGAGGTGCAGGCTGTGTCTCGCTGTGAC  923 
 
Query  808  TACTTCCTGGCCAAGATCCGCCAGGCAGATGTAGCACTTACT  849 
            ||||||||||||||||||   ||||||||||||||||| ||| 
Sbjct  924  TACTTCCTGGCCAAGATCAAGCAGGCAGATGTAGCACT-ACT  964 
 
 
CRISPR/Cas9 mutated cloned sequences 








































Clone 3: Sequence of pX458 + Rat TRIM32 CRISPR/Cas9 T1 target site (yellow) 
 
CTGTTAGAGAGATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATA 
CGTGACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTTAAAA 
TGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCT 
TGTGGAAAGGACGAAACACCGAAGATTTCCGCTGCATCGCGTTTTAGAGCTAGAAATAGC 
AAGTTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTT 
TTGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGC 
CAATTCTGCAGACAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCG 
CCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATAGGGACT 
TTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAA 
GTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGG 
CATTGTGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTA 
GTCATCGCTATTACCATGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCC 
CCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATG 
GGGGCGGGGGGGGGGGGGGGGG 
 
 
 
